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ABC    avidin biotin complex 
AEC    3-amino-9-ethylcarbazole   
ACTH    adrenocorticotropic hormone 
AD    Alzheimers disease 
ANOVA   analysis of variance 
APC    adenomatosis polyposis coli 
APP    amyloid precursor protein 
BSA    bovine serum albumin 
CA    cornu ammonis 
CC    corpus callosum 
CCx    cerebellar cortex 
cDNA    complementary DNA 
CM    cerebellar marrow 
CNH     head of the caudate nucleus 
CNPase   2', 3'-cyclic nucleotide 3'-phosphodiesterase 
CNS    central nervous system 
CNV    ventral part of the caudate nucleus 
CP     caudate putamen 
Dex    Dexamethasone 
DHC   dorsal hippocampal commisure 
DMEM   Dulbeccos modified eagle medium 
EAE    experimental autoimmune encephalomyelitis 
EDTA   ethylenediaminetetraacetic acid 
ELISA   enzyme-linked immunosorbent assay 
FCS    foetal calf serum  
FGF2    fibroblast growth factor 
GC    glucocorticoid 
GCR    glucocorticoid receptor 
GFAP    glial fibrillary acidic protein 
GL    granular layer 
GM    growth medium 
GP     globus pallidus 
HDG    hilus of the dentate gyrus 
HLA    human leukocyte antigen 
HPRT    hypoxanthine phosphoribosyltransferase 
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ICC    immunocytochemistry 
IFN-β    interferone-β 
IHC    immunohistochemistry 
IN    inerpositus nucleus 
lAlv    lateral Alveus 
LCN   lateral part of the caudate nucleus 
LFB    Luxol fast blue  
lStr    lateral striatum 
MAG   myelin associated glycoprotein 
mAlv    medial alveus 
MBP    myelin basic protein 
MCN    medial caudate nucleus 
ML    molecular layer 
MMLV   moloney murine leukemia virus  
MOG    myelin associated glycoprotein 
MP    methylprednisolone 
MS    multiple sclerosis 
mStr     medial striatum    
Olig2    oligodendrocyte transcription factor 2 
OPC   oligodendrocyte progenitor cell 
PBS    phosphate bufferd saline 
PDGFRα   platelet-derived growth factor receptor alpha 
PDGF-αα   platelet derived growth factor  
PL    pyramidal layer 
PLP    proteolipoprotein 
rtRT-PCR   reverse-transcription real time polymerase chain reaction 
sAPP    secreted amyloid precursor protein 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEM    standard error of the mean 
SVZ    subventricular zone 
SLM    stratum lacunosum moleculare 
T3    triiodothyronine 
TCR    T-cell receptor 
TNF    tumor necrosis factor  
WM    white matter 
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1. General introduction 
 
1.1 Multiple sclerosis in history and present 
Multiple sclerosis (MS) is a disorder of the central nervous system (CNS), 
characterized by myelin loss, varying degrees of axonal pathology, and progressive 
neurological dysfunction. Demyelination and a pronounced inflammatory infiltrate, 
composed of mainly lymphocytes, macrophages, and activated microglia are 
commonly observed in active MS lesions. Tissue changes, including neuronal 
damage, oligodendrocyte loss, as well as astrogliosis and signs of remyelination, 
accompany inflammation (Hemmer et al. 2002). The disease is preferably affecting 
young adults between 20 and 40 years with an average onset at 30 years. Patients 
younger than 15 or older than 55 are rarely diagnosed with MS. However, about 50 
children, predominantly girls, are diagnosed with MS every year in Germany (female-
to-male ratio, 2.8 vs. 1.8.). Children need longer from disease onset to reach the so 
called “secondary progressive stage”, but nevertheless do so at younger age 
(Renoux et al. 2007). Worldwide, 120,000 to 140,000 patients are diagnosed with MS 
(overall female-to-male ratio ~ 2:1) making it the most common chronic-inflammatory 
disease of the CNS (Friedrich 2008; Sellner et al. 2011). 
Historically, MS-related symptoms can be traced back to the early middle ages. The 
Island Saga by St. Thorlakr reports of the Viking women Hala (1293-1323), suffering 
of speech disorders and blindness. Oblations and prayers relieved her symptoms as 
can be expected in a relapsing-remitting disease course (Friedrich 2008; Poser 
1995). 
The best known MS patient describing his disease course in a diary is Sir Augustus 
D’Este, grandson of King George III (Firth 1941; Pearce 2005). He describes in detail 
his afflictions, varying from “indistinctness of vision“ in 1822 to “spasmodic pains in 
(…) Feet and Legs” as well as strong paresthesia and serious “attacks of Bile” in 
1846. Sir Augustus D’Este died in 1848 at the age of 54 years (Firth 1941). The first 
pathological elaboration on MS lesions can be annotated to Jean Cruveilhier (atlas 
completed in 1841) and Robert Carswell (atlas completed in 1838) (Compston 1988), 
whereas the first medical description was made by William McKenzie in 1840. He 
reported several cases of remitting visual loss in young people, compatible with optic 
neuritis (McDonald 1999; McKenzie 1840).  
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Picture 1 Jean Martin Charcot, 
Painting from  J. Desmoulin, 
about 1885 
In 1867, the French pathologist Jean Martin Charcot 
(1825-1893) gave the first full clinico-pathological 
description of MS. The illustration published in 
Ordenstein’s 1867 Parisian thesis represents the 
earliest summary of MS pathology in the spinal cord 
and the brain (Pearce 2005). He was the first to use 
the expression “sclerose en plaque” and to define 
diagnostic criteria (Friedrich 2008). MS has no “typical” 
course that would make the disease course 
predictable for both, patients and physicians. It can 
manifest in various ways and temporal patterns which 
led to the often heard denotation of “the disease with 
1000 faces.” Already in those days, the heterogeneous 
nature of the disease was emphasized. 
In 1996, Lublin and colleagues (Lublin and Reingold 1996) gave the following clinical 
criteria for MS-diagnosis: 
1. Relapsing-remitting MS is defined as “…episodes of acute worsening of 
neurologic function followed by a variable degree of recovery, with a stable 
course between attacks (Lublin and Reingold 1996).” 80–90% of cases start 
with a relapsing–remitting course. Over time, the number of relapses 
decreases, but most patients develop a secondary progressive phase of the 
disease in later stages (Hemmer et al. 2002).  
2. Secondary-progressive MS. Patients that initially present with a relapsing-
remitting disease course may develop “…progression with or without 
occasional relapses, minor remissions, and plateaus (Lublin and Reingold 
1996).”  
3. Primary–progressive MS is defined as “a gradual nearly continuously 
worsening baseline with minor fluctuations but no distinct relapses (Lublin and 
Reingold 1996).” This disease course affects about 10-20% of the patients 
(Hemmer et al. 2002). 
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Table 1 Histopathological characteristics of different patterns of active MS lesions (modified 
from Lucchinetti et al., 2000 and Rejdak et al., 2010) 
4. Progressive-relapsing MS. This is a rare clinical course, defined as 
…”progressive disease from onset, with clear acute relapses, with or without 
full recovery; periods between relapses characterized by continuing 
progression (Lublin and Reingold 1996).” 
 
Additionally, they gave two clinical definitions based on the severity of symptoms: 
“Benign MS” which was defined as “…disease in which the patient remains fully 
functional in all neurologic systems 15 years after disease onset” and “Malignant 
MS” which was defined as “…disease with a rapid progressive course, leading to 
significant disability in multiple neurologic systems or death in a relatively short time 
after disease onset (Lublin and Reingold 1996).” 
In 2000, Lucchinetti and colleagues described four distinct demyelinating lesions 
based on histological criteria. They postulated lesion types I and II as mainly T-cell–
mediated or T-cell plus antibody–mediated, whereas lesions III and IV are resulting of 
primary oligodendrocyte dystrophy (Lucchinetti et al. 2000).  
 
Given the complexity of MS, a clear diagnosis of MS is difficult. First neurological 
symptoms that are caused by demyelination or CNS inflammation are termed 
clinically isolated syndrome (CIS). A CIS does not fulfil the important hallmark of MS, 
dissemination in time. However, it may be indicative of MS (McDonald et al. 2001). In 
2001, McDonald and colleagues presented guidelines for MS diagnosis that have 
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been modified since then, most recently by Polman et al. in 2010 (McDonald et al. 
2001; Polman et al. 2011).  
Although intense research has been done since the first descriptions of MS, the 
cause of the disease is still unclear but is thought to be a combination of 
environmental exposure and genetic susceptibility (Compston and Coles 2008). 
 
1.2 Genetic risk factors 
A monozygotic twin whose sibling suffers from MS has a 50% lifetime risk to develop 
MS. The risk in first degree relatives ranges from 2% (parents; children) to 5% 
(siblings) and decreases to 1% in second- and third-degree relatives (Compston and 
Coles 2008). 
Most genes that have been identified to be involved in the susceptibility to develop 
MS are related to the immune system. In the 1970s, variations in the human 
leukocyte antigen (HLA) loci have been linked to a greater risk to develop MS. Since 
then, a growing number of genes have been identified, among genes that affect T-
cell function, immune cell regulation in general, tumor necrosis factor-α (TNFα) 
signalling as well as interferon- and vitamin D metabolism. Although the non-HLA 
genes only moderately influence MS susceptibility, their identification is of importance 
since this might lead to a better understanding of pathways involved in the 
development of MS (Nischwitz et al. 2011). 
 
1.3 Epidemiology  
MS prevalence is higher in the northern and southern latitudes compared to latitudes 
closer to the equator. Migrants from high- to low-prevalence areas display a reduced 
risk to develop MS. Interestingly, migrants originating from countries with low risk do 
not develop a higher risk of getting MS when moving to high risk countries (Gale and 
Martyn 1995). Age during movement is discussed to be a critical factor in this context 
(Kurtzke 1993). Two different hypotheses have been developed to explain MS 
epidemiology and the results of migration research. The prevalence hypothesis by 
Kurtzke and colleagues (Kurtzke 1993) postulates that MS is caused by a not yet 
identified pathogen that is more common in areas of high MS prevalence. It mainly 
bases on observations of MS incidence on the Faroe Islands. Before 1940, no MS 
cases have been reported on the Faroe, however, a high incidence was observed 
after the occupation by British troops during World War II. It is speculated that British 
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soldiers introduced a pathogen, formerly absent on the islands causing MS in a small 
proportion of those infected (Kurtzke 1993; Kurtzke and Heltberg 2001). 
The second hypothesis is called the hygiene hypothesis. Accordingly, exposure to 
several infectious agents early in life is protective against MS, whereas the same 
infection might trigger autoimmune reactions in susceptible individuals when it occurs 
later in life (Ascherio and Munger 2007a). The Ebstein-Barr virus has been identified 
as a potential infectious agent and there is convincing epidemiological evidence that 
it is a strong risk factor for MS development (Ascherio and Munger 2011). Anyhow, 
an Ebstein-Barr virus infection alone cannot explain some aspects of MS 
epidemiology, including the reduction in risk among migrants from high- to low-risk 
areas (Ascherio and Munger 2007b). 
Beyond that, several non-infectious factors have been identified to correlate with MS 
incidence (Ascherio and Munger 2007b). Sunlight exposure, vitamin D uptake and 
sex hormone levels are widely accepted to positively interfere with MS risk or disease 
progression. High sunlight exposure and vitamin D production and uptake have been 
found to reduce MS risk. For sex hormones, e.g. estrogen, it has been shown that 
they can decrease relapse rate and attenuate neuroinflammation (Ascherio and 
Munger 2007b; Confavreux et al. 1998; Kipp and Beyer 2009).  
A negative factor that increases MS risk is smoking. Furthermore, it has been 
associated with an accelerated transition from relapsing-remitting to secondary 
progressive MS (Ascherio and Munger 2007b; Kipp and Beyer 2009).  
Although many other factors (e.g. dietary factors or stress) have been discussed to 
be involved in MS risk or pathology, their role remains to be further investigated.   
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1.4 Therapeutic attempts for the treatment of MS 
In Germany, the “Multiple Sklerose Therapie Konsensus Gruppe” and the “Deutsche 
Gesellschaft für Neurologie” defined guidelines for the treatment of MS patients. They 
distinguish between acute relapse-therapy, long term immuno-modulating- and 
symptomatic-therapy. 
In accordance to their guidelines, acute relapses are usually treated with a high dose 
methylprednisolone (MP) pulse therapy (1000mg/day for 3 consecutive days) which 
is a synthetic glucocorticoid dampening the acute inflammatory responses and 
stabilizing the blood brain barrier. In rare cases, escalating relapses can be treated 
additionally with a plasmapheresis. 
Currently, five immuno-modulating agents are approved for the long term treatment 
of MS patients in Europe: Beta-interferon (IFN-β), glatiramer acetate, a random 
polymer of 4 amino acids found in Myelin basic protein (MBP), Azathioprin and 
Mitoxantron, which are cytostatic drugs and Natalizumab, a monoclonal antibody. 
Due to their well toleration, first choice agents are IFN-β and glatiramer acetate that 
might be replaced by one of the other agents if indicated (for example in very 
aggressive MS courses). Medication is often completed by additional symptomatic 
treatments, depending on the individual patient’s needs. It should be pointed out that 
all available treatments are symptomatic and healing of MS is not possible so far. 
Amelioration of remyelination has come into the focus of research, since recent data 
Picture 2 World distribution of MS risk.   
Source: http://www.unitedspinal.org/msscene/2009/10/06/mapping-multiple-sclerosis 
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demonstrate that myelin sheaths play an important role in maintaining the axonal 
integrity and protecting neurons (Irvine and Blakemore 2008). 
 
1.5 Animal models for MS 
The vast majority of MS-related experimental studies rely on the autoimmune model 
of experimental autoimmune encephalomyelitis (EAE). EAE can be induced by the 
active sensitization to CNS tissue, myelin or different protein antigens of the CNS or 
by the passive transfer of auto reactive T-cells. Another option is to make use of T-
cell receptor (TCR) transgenic mice, for instance using a myelin oligodendrocyte 
glycoprotein (MOG)-specific TCR. Such mice develop spontaneous inflammatory 
disease in the CNS (Bettelli et al. 2003; Lassmann 2008; Madsen et al. 1999). 
Chronic virus-induced inflammation and demyelination in the CNS is an alternative 
model for MS. Theiler’s virus encephalomyelitis appears to be the most reliable and 
most frequently used virus-induced MS model. Despite major differences in the 
etiology and pathogenesis between autoimmune-mediated and virus-induced 
demyelinating diseases, similar patterns of demyelination and remyelination suggest 
common basic mechanisms for tissue injury and repair (Lassmann 2008; Lipton et al. 
2005; Rodriguez 2007). These models, in their broad spectrum, are useful tools to 
study specific aspects of MS pathology and pathogenesis but none of them mimics 
the disease as a whole. 
 
1.6 The cuprizone model for MS 
Since MS is a very complex and heterogeneous disease, reductionistic animal 
models are needed to investigate and uncover distinct pathological processes and 
repair mechanisms. In the cuprizone mouse model, the orally administered copper 
chelator cuprizone (bis(cyclo-hexanone)oxaldihydrazone) causes a highly 
reproducible demyelination of distinct brain regions, among them the corpus callosum 
(CC). The CC represents the most frequently investigated white matter tract in this 
model. Demyelination can be induced in an “acute” manner by supplementing the 
chow with 0.2% (w/w) cuprizone for 5-6 weeks or in a “chronic” manner by prolonged 
intoxication for 12 weeks or even longer. Acute demyelination is followed by 
spontaneous remyelination during subsequent weeks when mice are fed normal 
chow. In contrast, remyelination is highly restricted after chronic demyelination. 
Cuprizone susceptibility is dependent on strain, age and weight of the animals (Irvine 
and Blakemore 2008; Skripuletz et al. 2008).   
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The cuprizone model is thought to best mimic human pattern III lesions (Kipp et al. 
2009; Lucchinetti et al. 2000). In fact, some similarities exist between human pattern 
III lesions and cuprizone-triggered demyelination: Myelin associated glycoprotein 
(MAG) mRNA levels seem to be more down regulated during early demyelination 
compared to other myelin protein markers, demyelination does not present in a 
perivenous distribution, borders are ill-defined and pronounced oligodendrocyte 
apoptosis can be found in active demyelinating lesions. However, other features of 
pattern III lesions, such as inflamed blood vessels and the presence of CD3+ T-cells, 
are not observed in the cuprizone model. The later might be due to a direct 
suppression of cuprizone on T-cell function (Mana et al. 2009). The biochemical 
events leading to oligodendrocyte damage in response to cuprizone treatment are 
cryptically. Although cuprizone is a copper chelator, there is a controversial 
discussion of changes in CNS copper levels during the toxic challenge. Furthermore, 
the mechanisms responsible for oligodendroglial death in MS lesions are not clear. It 
is questionable whether similar pathomechanisms are responsible for 
oligodendroglial loss in MS lesions and in the cuprizone model. Thus, one might ask 
whether cuprizone-induced demyelination models myelin loss observed in human MS 
patients. This assumption is often challenged by experts in the field. However, one 
should notice that MS is presently regarded as a disorder with many different 
features and facets. No current experimental animal model covers the entire 
complexity of MS. Instead, the various animal models and intoxications can be 
applied to selectively investigate and uncover distinct pathological processes and 
repair mechanisms of MS (Kipp et al. 2009).  
 
1.7 Astrocytes in MS and during CNS inflammation 
Besides lymphocytes, astroglia and microglia contribute to the cellular composition of 
inflammation in MS lesions (van der Valk and De Groot 2000). Astroglia are pivotal 
regulators of intra-cerebral inflammatory processes and are required to protect nerve 
cells from pathological threats. Activation, proliferation, and morphological alterations 
of astrocytes are histopathological hallmarks of MS and its related animals models, 
i.e. EAE and toxin- and virus-induced demyelination (Gold et al. 2006; Kipp et al. 
2009; Lassmann 2008).  
The sclerotic aspect in MS pathology is due to a tissue scar formed mainly by 
astrocytes but also other glia cells such as microglia and oligodendrocytes. In the 
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most common type of MS, plaques of demyelination are interspersed with and 
surrounded by reactive astrocytes. In addition, widespread focal reactive astrogliosis 
of varying intensity throughout the white and grey matter is characteristic for the 
disease. Astrocytes during MS may also demonstrate the phenomenon of 
”emperipolesis”, i.e., an astrocyte apparently engulfing one or more other cells such 
as oligodendroglia (Ghatak 1992) and lymphocytes (Furer et al. 1993). The role of 
astrocytes during MS and related disorders is under intense investigation. Astrocytes 
play an active role during degeneration and demyelination by promoting 
inflammation, damage of oligodendrocytes and axons, and glial scarring but might 
also be beneficial by creating a permissive environment for remyelination and 
oligodendrocyte precursor migration, proliferation, and differentiation. Astrocytes 
secrete a multitude of harmful cytokines such as TNF-α or interleukin 1β (IL1β) as 
well as pro-inflammatory prostaglandins (Kipp et al. 2007; Kipp et al. 2008). This 
makes it likely that astrocytes are implicated in oligodendrocyte damage and, in 
consequence, in promoting demyelination. Astrocytes might contribute to 
regeneration and remyelination by secreting important growth factors, i.e., platelet-
derived growth factor (PDGF), insulin-like growth factor 1 (IGF1), and basic fibroblast 
growth factor (FGF-2). All of these factors are known to promote remyelination and 
prevent oligodendrocyte apoptosis. On the other hand, it has been shown that the 
glycosaminoglycan hyaluronan, synthesized by activated astrocytes, accumulates in 
chronically demyelinated MS lesions and inhibits oligodendrocyte progenitor (OPC) 
differentiation and consequently remyelination in vivo (Back et al. 2005). Of relevance 
is a recently published review article which focuses on astrocytes as producers of 
secreted factors that can either promote or impede myelination within the CNS and 
how these cells are currently thought to be involved in the myelin pathology of MS 
(Moore et al. 2011). 
We stress at this point that the secretion of pro-inflammatory molecules such as TNF-
α or IL-1β from astrocytes does not necessarily has a negative impact on MS disease 
progression. The importance of inflammation for reparative processes such as 
remyelination is well-documented (Patani et al. 2007). The cytokines TNF-α and IL-
1β promote proliferation of OPC and, in consequence, remyelination (Arnett et al. 
2001; Mason et al. 2001). Major histocompatibility complex-II (MHC-II)-null mice 
display delayed remyelination and regeneration of oligodendrocytes compared to 
their wild type littermates after cuprizone- or Theiler's virus-induced demyelination 
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(Arnett et al. 2003; Njenga et al. 1999). Furthermore, the activation of an 
inflammatory response by a combination of growth factors leads to myelin repair 
(Biancotti et al. 2008) clearly demonstrating a beneficial role for inflammation in the 
CNS. Other factors related to inflammation, such as interferon-γ (Lin et al. 2006; 
Mana et al. 2009), however, might be more detrimental for remyelination. 
Understanding of the dual role of inflammatory cytokines/factors to enable control 
and manipulation of these responses thus represents a major goal for the 
development of new therapies.  
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2. Scope of the study 
 
Our research group aimed to characterize the cuprizone mouse model in detail with 
regard to regional susceptibility for myelin loss and innate immune resposes. One 
hallmark of MS is dissemination in space. We, therefore, investigated the mouse 
basal ganglia, hippocampus, and cerebellum, and performed histopathological and 
gene expression studies of these brain regions. The focus of my reserach was the 
intrinsic inflammatory response (e.g. astrocyte and microglia activation) and the 
kinetic and magnitude of demyelination in white and grey matter areas of the 
cerebellum. Results and discussion are given in Chapter I. 
 
As already mentioned, glucocorticoids (GC) are the gold standard in treating acute 
MS relapses but not much is known whether and how they also interfere with 
regenerative processes. To be able to distinguish between the immunomodulating 
effects of GC and direct effects on repair capacity of the brain, we used the potential 
of non-immune driven cuprizone intoxication to serve as a model for spontaneous 
repair/remyelination. We investigated the effects of high dose GC treatment on the 
remyelination capacity of the mouse brain in vivo and addressed the underlying 
mechanisms by in vitro models. Results are summarized and discussed in Chapter 
II. 
 
Recent and ongoing research in our lab focuses on the role of glia cells, in particular 
astrocytes, during reparative and inflammatory processes in the brain. Amyloid 
precursor protein (APP) positive glia cells can be found in MS lesions (Gehrmann et 
al. 1995). Although not much is known about the biology of glia-derived APP, it is 
thought to be involved in brain intrinsic inflammatory responses. In the third part, we 
addressed APP expression in the cuprizone model for MS. Results are given and 
discussed in Chapter III. 
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3. Materials and methods 
 
3.1 Animal treatment and induction of demyelination and remyelination 
C57BL/6 male mice were obtained from Harlan Winkelmann (Borchen, Germany). 
Animals underwent routine cage maintenance once a week and microbiological 
monitoring according to the Federation of European Laboratory Animal Science 
Associations recommendations. Food (Sniff Spezialdiäten, Germany) and water were 
available ad libitum. Research and animal care procedures were approved by the 
Review Board for the Care of Animal Subjects of the district government (North 
Rhine-Westphalia, Germany) and performed according to international guidelines on 
the use of laboratory animals. Demyelination was induced by feeding 20g +/- 1g 
(app. 8 weeks old) male C57BL/6 mice a diet containing 0.2% cuprizone (Sigma-
Aldrich Inc., Germany) mixed into a powdered ground standard rodent chow (Sniff 
Spezialdiäten, Germany) for the indicated period (up to 7 weeks, depending on the 
experimental analysis) and animals were sacrificed at the indicated time point.  
For remyelination studies, the animals were divided into experimental groups I – VI 
(compare figure 7). Group I received normal chow during the indicated time point, 
whereas animals from group II-VI were fed cuprizone for 5 weeks to induce acute 
demyelination of the CC. Group II was sacrificed at week 5 to demonstrate 
demyelination. Group III received 9 days, group IV 21 days vehicle (NaCl) injection, 
respectively to allow animals to recover (i.e. remyelination). Group V and VI were 
treated every day with intra peritoneal (i.p.) MP (Urbasol, Sanofi-Aventis, Germany; 
15 mg/kg body weight) for the respective period. Animals that were used for 
triiodthyronin (T3) ELISA analysis were allowed to recover for 3 days, receiving MP 
(15mg/kg body weight) or NaCl, respectively, every day. 
For histological/immunohistochemical analysis, mice were transcardially perfused 
with 2 % paraformaldehyde containing 1.5 % saturated picric acid (for perfusion 
solution and detailed procedure, see Appendix 1) after the indicated period as 
published (Groebe et al. 2009; Norkute et al.; Pott et al. 2009). 
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3.2 Tissue preparation  
After perfusion (Appendix 1) and overnight post fixation in the same fixative, brains 
were dissected. Embedded brains (details of the embedding procedure are 
summarized in Appendix 2) were coronally sectioned each 5 µm in thickness. 
Investigated levels according to Sidman et al. (http://www.hms.harvard.edu/research 
/brain/atlas.html) were 455, 465, and 475 (cerebellum), levels 285, 305, and 325 
(hippocampus) and levels 215 and 265 (APP, corpus callosum). For gene expression 
analysis, mice were killed by rapid decapitation. Brains were quickly removed and the 
brain areas of interest (entire cerebellum without the cerebellar peduncles, the entire 
hippocampus, and the basal ganglia at the level of the commisura anterior, the entire 
CC and the cerebral cortex) separated using a stereomicroscopic approach. All 
tissues were immediately shock-frozen in liquid nitrogen and kept at -80°C until used. 
 
3.3 Luxol fast blue (LFB) staining and immunohistochemistry (IHC) 
For LFB staining, 5 µm-thick sections were placed on superfrost glass slides (Thermo 
Fischer, Germany). Sections were deparaffinised in 2 x 10 min xylol, rinsed in 2 x 10 
min 100% ethanol and 2 x 5 min 95% ethanol, then incubated in a LFB solution 
(0.01% in 95% ethanol) overnight at 60°C. Sections were processed in a lithium 
carbonate solution (0.05% in bidest. H2O; Roth, Germany), differentiated in 70% 
ethanol and counterstained with cresyl violet (myelinated fibers appear blue, the 
neuropil pink, and nerve cells purple). 
For IHC, 5 μm-thick sections were placed on superfrost glass slides (Thermo Fischer, 
Germany). Sections were rehydrated and heat-unmasked where advantageous (see 
table 2), blocked with PBS containing 2% normal horse serum for 1 h, and incubated 
overnight with the primary antibody diluted in blocking solution (for the detailed 
procedure, see Appendix 3). Anti proteolipoprotein (PLP) antibody, anti 2', 3'-cyclic 
nucleotide 3'-phosphodiesterase (CNPase) antibody and anti-MAG antibody (rabbit 
IgG; Santa Cruz, Germany) were used as myelin markers, whereas glial fibrillary 
acidic protein (GFAP) was used to visualize astrocytes. Anti-oligodendrocyte 
transcription factor-2 (Olig2) antibody was used to visualize OPC, whereas anti-
Adenomatous Polyposis Coli (APC) antibody was used to detect mature 
oligodendrocyte cell bodies. Ionized calcium binding adapter protein 1 (Iba-1) was 
used as a marker to detect microglia/macrophages. This protein has been proven as 
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a valid marker for microglia as well as macrophages (Cheung et al. 2008; Wells et al. 
2005). An overview of all primary antibodies used in this work is given in table 2. 
 
 
 
 
After washing for 2 x 5 min in PBS, sections were incubated with biotinylated 
secondary antibodies for 1 hour, followed by peroxidase-coupled avidin-biotin-
complex (ABC kit, Vector Laboratories, UK). The immune-precipitated product was 
visualized with the ACE reaction (Invitrogen, Germany) following the suppliers 
protocol until satisfying staining intensity was achieved and reaction was stopped in 
H2O. Slides were mounted with Kaiser's glycerine gelatine (Merck, Germany). 
Stained and processed sections were documented with a Nikon ECLIPSE 55i 
camera. For double-staining, the following fluorescently-labeled secondary antibodies 
were applied over night at 4°C: Alexa Flour 488 donkey anti-mouse IgG or Alexa 
Flour 568 goat anti-rabbit IgG. Sections were analyzed by laser-fluorescent 
Table 2 Information about used primary antibodies and the respective concentrations are summarized.  
ICC = Immunocytochemistry; IHC = Immunohistochemistry; AGR = antigen retrival; WB = western blot 
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microscopy (Zeiss Axiophot) or confocal microscopy (LSM 710, Zeiss, Germany). An 
overview of all secondary antibodies is given in table 3. 
 
 
 
 
 
 
3.4 Immunocytochemistry (ICC) 
ICC to detect the expression of glucocorticoid receptor (GCR) and GFAP in primary 
astrocyte cultures was performed using appropriate secondary fluorescence 
antibodies (Alexa Fluor 488 and Alexa Fluor 568; table 3). Therefore, cells were 
grown on poly-L-ornithin (Sigma, Germany) coated glass slides in 24 well plates. 
Fixation was performed for 20 min in 3.7% formalin (Roth, Germany), washed 2 x 
5min in PBS and kept at 4°C until used. Cells were permeabilized by incubating in 
0.2% Tween 20 for 10 min. After washing for 2 x 5 min in PBS, the slides were 
incubated for 20 min with 1% bovine serum albumin (BSA) in PBS to block unspecific 
antibody binding. Primary antibody was diluted in 1% BSA in PBS and cells 
incubated over night at 4°C. After washing for 3 x 5 min in PBS, counterstaining with 
1µg/ml Hoechst (Invitrogen, Germany) for 10 min, and additional washing for 3 x 
5min in PBS, slides were mounted in Fluor PreserveTM (EMD Biosciences, USA) and 
analyzed by laser-fluorescent microscopy (Axiophot, Zeiss, Germany). 
 
Table 3 Information about used secondary antibodies and respective concentrations are summarized.  
ICC = Immunocytochemistry; IHC = Immunohistochemistry; WB = western blot 
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3.5 Quantification of demyelination 
Immunohistological investigations of myelination were performed at the levels 215, 
265 (basal ganglia and CC), 285, 305, 325 (hippocampus), 465 and 475 (cerebellum) 
according to the mouse brain atlas by Sidman et al. Four to five animals/group were 
included. Each two to three slices (5µm) per animal, investigated brain region, and 
indicated time point were examined. All manual scorings were performed by at least 
2 experienced and blinded observers.  
See Figure 1A/B for cerebellar subregions. Additionally, densitometric measures of 
the CC were performed on binary converted pictures using the freely available 
ImageJ-software (National Institute of Health, USA) giving similar results. To this end, 
pictures were taken from the medial and lateral parts of the CC, resulting in a total of 
6 pictures per animal, investigated brain region, and indicated time point.  
 
3.6 Quantification of oligodendrocyte cell numbers 
Quantification of oligodendrocytes was achieved by manual counting the number of 
APC-positive cells in the investigated regions. At least two slices per animal, 
investigated brain region, and indicated time point were analyzed by at least two 
independent observers. Cell numbers were calculated and expressed per mm2. Cell 
counting was performed using an Axiophot microscope (Zeiss, Germany) and a 10x 
objective in the cerebellum, CC and hippocampus region (including cells in the DHC, 
the SLM and the hilus of the dentate gyrus (HDG) and the fimbria region) and a 40x 
objective at the basal ganglia level. Cell counting was performed with a Nikon 
ECLIPSE 55i microscope. 
 
3.7 Quantification of astrocyte parameters 
Since astrocytosis may result from hypertrophy or hyperplasia, quantification of 
astrocyte parameters was performed in the cerebellar cortex and cerebellar marrow, 
in the hippocampal SLM and the HDG, the basal ganglia and CC. To determine 
hyperplasia of astrocytes, GFAP-positive cells with a clearly visible nucleus were 
counted in three different sections per animal, investigated brain level, and time point. 
Cell numbers were calculated and expressed per mm2. Cell counting was performed 
using the Axiophot microscope (Zeiss, Germany) and a 10x or 40x objective. To 
quantify hypertrophy of astrocytes, the area occupied by GFAP-positive astrocytes 
with a clearly visible nucleus was measured using a morphometric device and the 
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respective imaging software (NIS elements AR 2.30, Leica, Germany). This 
measurement was performed using a 40x objective. Data are finally expressed as 
µm2 area/cell.  
 
3.8 Real-time reverse transcriptase-polymerase chain reaction (rtRT-PCR) 
Gene expression was measured using the rtRT-PCR technology (BioRad, Germany), 
QTM SYBR Green Supermix (Bioline, Germany), and a standardized protocol. 
Isolation of total tissue RNA was performed with NucleoSpin kit (Macherey-Nagel, 
Germany). For cell culture experiments, RNA was isolated with PeqGold (PeqLab, 
Germany). RNA concentration and purity were assessed using the OD260 and 
OD260/OD280 ratios, respectively, and reverse transcribed using an Invitrogen 
MMLV RT-kit and random hexanucleotide primers (both Invitrogen, Germany). PCR 
reactions were carried out in a reaction mixture consisting of 2 μl cDNA, 2 μl RNAse-
free water (Invitrogen, Germany), 5 μl QTM SYBR Green Supermix (BioLine, 
Germany), and 0.5 μl of primer (100 pmol/µl) in standard tubes using the MyIQ rtPCR 
Detection System (BioRad, Germany) under following conditions: 10 min enzyme 
activation at 95°C, 45 cycles of 15 s denaturation at 95°C, 30 s annealing at 
individual temperatures, 30 s amplification at 72°C, and 5 s fluorescence 
measurement at 80°C. Primer sequences are shown in table 4. Relative 
quantification was performed using the ΔCt method which results in ratios between 
target genes and a housekeeping reference gene (HPRT) (Kipp et al. 2008). As the 
validity of this method critically depends on the constant expression of the 
housekeeping gene, constant expression of HPRT was tested against other 
housekeeping genes (not shown). In each run, external standard curves were 
generated by several fold dilutions of target genes. The concentration of the target 
genes was calculated by comparing Ct values in each sample with Ct values of the 
internal standard curve. Finally, data were expressed as the ratio of the amount of 
each transcript versus the concentration of HPRT. Melting curves and gel 
electrophoresis of the PCR products were routinely performed to determine the 
specificity of the PCR reaction (not shown). 
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3.9 Adrenocorticotrop hormone (ACTH) and T3 ELISA 
About 1 ml blood of mice was collected by cardiac puncture and incubated at room 
temperature for 30 min. After centrifugation at 2000 x g for 10 min, serum-
supernatant was collected and stored at -20°C until used. ELISA was performed in 
96-well plates according to the manufactures instructions (mdbiosciences, 
Switzerland (ACTH) and GenWay, USA (T3)). Absorbance was measured with a 
TECAN ELISA-reader at 450 nm (ACTH-concentrations to 150 pg/ml and T3 ELISA) 
and 405 nm to be able to interpolate to concentrations higher than 150 pg/ml (ACTH 
only), as recommended by the supplier. 
 
Table 4 Primer sequences and lenght of the resulting product in bp. 
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3.10 Cell culture experiments 
3.10.1 Primary oligodendrocyte progenitor cells (OPC) and neonatal astrocyte 
cultures  
OPC cultures were established following a modified protocol as described previously 
(Richter-Landsberg and Vollgraf 1998). One to three day old rat pups were killed by 
rapid decapitation, cerebral cortices were dissected, meninges and blood vessels 
removed and dispersed in growth medium (GM) consisting of Dulbecco’s modified 
Eagle’s medium (DMEM, Invitrogen, Germany) containing 10 % heat inactivated 
foetal calf serum (FCS) (PAA, Austria) and the antibiotics penicillin/streptomycin 
(0.5 %, Gibco, Germany). Tissues were pooled, homogenized with a pipette, and 
cells were seeded in GM in 50 ml flasks (Greiner, Germany). They were allowed to 
grow for 4 days, followed by a GM change every third day. After approximately 14 
days in culture, an astrocyte monolayer had formed on the bottom of the flasks with 
microglia and OPC growing on top. For OPC isolation, GM was replaced, cells 
incubated for 1 h in the incubator and agitated at 100 rpm for 2 h at 37°C to remove 
debris, dead cells, and microglia. Subsequently, flasks were washed with pre-
warmed PBS, incubated with 7 ml of GM for 1 h at 37°C 5 % CO2, and placed on the 
shaker at 240 rpm and 37°C for 18 h to de-attach OPC from the astrocyte monolayer. 
GM was removed, flasks were washed gently with pre-warmed PBS and both, 
collected GM and PBS, were combined. Collected OPC were centrifuged for 10 min 
at 800 x g, pellet containing OPC re-suspended in 10 ml GM, and seeded at a 
density of 2 x 106 cells/well on poly-L-ornithin (Sigma, Germany) coated 6-well plates. 
After 1 h, cells were gently washed with 37 °C PBS and incubated in 37 °C DMEM 
plus supplement (insulin- (5 µg/ml) transferrin- (5 µg/ml) sodium selenite- (25 ng/ml; 
Boehringer, Germany). Dexamethasone (Dex) treatment was started directly after 
washing (10-6 M; Sigma-Aldrich, Germany).  
Primary astrocytes were prepared from 2-to-4-day-old Balb/c mice (Harlan 
Winkelmann, Germany) as described in detail previously (Braun et al. 2009). Briefly, 
cerebral cortices were dissected, meninges removed and dispersed in Dulbecco’s 
phosphate-buffered saline containing 1% trypsin and 0.02% ethylene-
diaminetetraacetic acid (EDTA), filtered through a 50-mm nylon mesh, and 
centrifuged at 400 x g for 5 min. Cells were re-suspended in DMEM (Invitrogen, 
Germany) containing 20% heat-inactivated fetal calf serum (PAA, Austria), 
streptomycin (0.5%) and fungizone (0.1%, both from Invitrogen, Germany). Finally, 
 26
cells were seeded in 100 mm plates coated with poly-L-ornithin (Sigma, Germany) at 
a density of 1–2 x 106 cells per cm2. Astrocytes were cultured at 37 °C in a humidified 
incubator with 5% CO2. Medium was replaced every third day. Upon reaching 
confluency, cells were trypsinized and replated at a lower density. This procedure 
was repeated twice. The resulting final astroglia culture is characterized by >95% 
homogeneity of glial fibrillary acidic protein positive cells (Braun et al. 2009; Pawlak 
et al. 2005).  
 
3.10.2 Cell culture treatment 
For MP or Dex treatment, steroids (both from Sigma-Aldrich, Germany) were 
dissolved in ethanol (100 % p.a. quality) at concentrations of 10-3 M, and further 
diluted in 1 x PBS to yield final dilutions. Appropriate concentrations of ethanol were 
added in control groups. CS treatment of OPC was performed at day 0 and, after 
changing the medium, at day 3. CS treatment of astrocytes was performed on day 0 
for 24h.  
Fibroblast growth factor (FGF2) and platelet derived growth factor (PDGF-αα); (both 
Peprotech, Germany) were dissolved in 1 x PBS and applied in a final concentration 
of 5 ng/ml each.  
LPS (Sigma-Aldrich, Germany; 100 ng/ml), TNFα (Invitrogen, Germany; 100 ng/ml), 
glutamate (Sigma-Aldrich, Germany; 4 μM) or H2O2 (Roth, Germany; 200 μM) 
treatment of astrocytes was performed for 24 h. Previous studies revealed that the 
applied concentrations are sufficient to activate astrocytes, however, are not toxic in 
the applied concentrations (Braun et al. 2009).  
 
3.11 Western blot 
Western blot analysis was performed following a modified protocol as published 
previously (Kramer et al. 2010; Norkute et al. 2010). For in vivo studies, the 
appropriate brain areas were dissected and snap frozen as described above, 
proteins isolated and finally dissolved in PLB-TCEP provided with the NucleoSpin® 
RNA/Protein kit (Machery-Nagel, Germany). Protein concentrations were determined 
using the trichloracetic acid method (Kramer et al. 2010). Subsequently, same 
amounts of protein (10-14 µg) were loaded on each lane, separated by 8% SDS poly 
acrylamide gel electrophoresis (SDS-PAGE; for details see Appendix 4) and blotted 
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onto a nitrocellulose membrane (Hybond, amersham pharmacia biotech, Great 
Britain) for 1 h at 10V.  
For in vitro studies, cell culture-derived protein was isolated using RIPA buffer 
(50 mM Tris HCl pH = 8; 150 mM NaCl; 1 % NP-40; 0.5 % sodium deoxycholat; 
0.1 % SDS) containing complete Mini Protease inhibitor cocktail tablets (Roche, 
Germany) according to the manufacturer's recommendation. Cells were harvested by 
scraping, washed and centrifuged. Supernatant was collected and protein 
concentration determined by Pierce BCATM Protein Assay Kit (Thermo Fischer, USA). 
Same amounts of protein (10 µg) were electrophoretically separated on 8% to 10 % 
polyacrylamide gels (depending on the size of the target protein) and then transferred 
onto nitrocellulose membranes (BioRad, Germany) for 1 h at 10 V. The nitrocellulose 
membranes were blocked after washing in PBS (3 x 5 min) with 5 % fat-free milk 
solution in PBS for 30 min. The membranes were then incubated with primary 
antibodies diluted in 5 % milk in PBS-Tween over night at 4 °C. After washing with 
PBS, appropriate secondary antibodies conjugated to horse-radish peroxidase were 
added to the membranes and incubated for 2 h at room temperature (see tables 2 
and 3 for antibodies and dilutions). The membranes were washed 3 x 5 min with PBS 
and then incubated with commercial enhanced chemoluminescence reagent kit (ABC 
Kit, Amersham Bioscience, UK) and subsequently exposed to X-ray film (Kodak, 
Germany). 
 
3.12 Statistical analysis 
Chapter I: 4-5 mice each were used for immunocytochemistry and gene expression 
analysis per experimental group in all experiments. For cell counting, staging of 
myelination, and analyzing cell volumina, an independent sample t-test was 
performed. For gene expression analysis and quantification of cells, differences 
between groups were statistically tested by an analysis of variance (ANOVA) 
followed by a Tukey’s post-hoc multiple-range test using SPSS software (SPSS Inc., 
Chicago, IL, USA). All data are given as arithmetic means ± SEM. P values of the 
different analyses with p<0.05 were considered to be statistically different.  
Chapter II: Number of animals used: Group I: 9 animals; II: 7 animals; III: 8 animals; 
IV: 3 animals; V: 9 animals; VI: 3 animals. Results of cell counting and analysis of 
myelination index were compared by independent sample t-tests. For gene 
expression analysis, statistics were made using data from all experiments. GraphPad 
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Prism version 5.00 for Windows, GraphPad Software, San Diego California USA was 
used for statistical analysis and preparation of graphs. For gene expression analysis, 
differences between groups were statistically tested by ANOVA followed by a Tukey’s 
post-hoc multiple-range test using GraphPad software. All data are given as 
arithmetic means ± SEM. P values <0.05 were considered to be statistically different. 
Cell culture experiments regarding OPC differentiation consisted of n = 4 
independent experiments. Experiments regarding growth factor supplementations of 
OPC were performed twice. All other cell culture experiments were conducted at 
least three times.  
All in vivo experimental groups included in Chapter III consisted of at least 4 animals 
per group. Cell culture experiments have been conducted 3 times independently and 
differences between groups were statistically tested by ANOVA followed by a Tukey’s 
post-hoc multiple-range test using GraphPad software. 
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4. Chapter I  
 
Characterization of demyelination and innate immune 
responses in the cuprizone mouse model 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parts of this chapter have been published in: 
  
Angela Groebe*, Tim Clarner*, Werner Baumgartner, Cordian Beyer and Markus 
Kipp  
“Cuprizone treatment induces distinct demyelination, astrocytosis and microglia cell 
invasion/proliferation in the mouse cerebellum.” 
Cerebellum, (2009) 8:163–174 
*contributed equally as first authors 
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4.1 Introduction 
Our group intended to uncover histopathological and molecular changes within three 
different brain regions in cuprizone-treated animals. The CC and the cerebral cortex 
are well-investigated brain regions in this animal model and served as white and grey 
matter controls. 
One area of interest was the mouse cerebellum, a well-known part of the brain 
involved in demyelinating events in MS (Gilmore et al. 2008; Kutzelnigg et al. 2007; 
Pokryszko-Dragan et al. 2008) and EAE (Craner et al. 2003; Tonra 2002). In MS, the 
brain stem and cerebellum are frequently sites of damage and appear to play a 
decisive role for clinically-isolated syndromes associated with MS. It is very likely that 
lesions located in these brain structures have an important impact on the 
development of disability in the definite forms of the disease (Yousry et al. 2000). 
Cerebellar dysfunction in MS is a significant contributor to disability, is relatively 
refractory to symptomatic therapy, and often progresses despite treatment with 
disease-modifying agents. Thus, there is a need for better understanding of its 
pathophysiology.  
Determination of behavioural deficits is important to reveal beneficial therapeutic 
effects reflecting functional stabilization and/or recovery  in various animal models 
affecting the CNS. Some studies reported behavioural deficits in the cuprizone 
model. It was reported that after 5 weeks of cuprizone treatment, sensorimotor 
reactivity was affected as determined by the rota-rod test (Franco-Pons et al. 2007). 
Motor skill deficits were also reported by another group after cuprizone exposure 
using a more advanced testing battery, namely the motor skill sequence test 
(Liebetanz and Merkler 2006). Affected motor skill performance in cuprizone exposed 
animals is thought to be due to commissural demyelination such as the CC 
(Matsushima and Morell 2001). However, poor outcome on motor skill performance 
testing might also be due to an involvement of other brain areas, above all the 
cerebellum. 
We have recently published a study of the basal ganglia system (Pott et al. 2009) 
which is frequently involved in MS pathology as well (Hasan et al. 2009; Henry et al. 
2008; Nociti et al. 2008; Pirko et al. 2007). In this report, we came to the conclusion 
that "Smaller values in the absolute volume of the caudate nucleus (CN) and in 
relation to total intracranial volume were observed in relapsing-remitting patients 
compared to healthy controls (Hasan et al. 2009). Demyelination and 
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neurodegeneration within the basal ganglia has been linked to several MS symptoms 
such as fatigue (DeLuca et al. 2008; Leocani et al. 2008), impairment of memory 
(Benedict et al. 2009; Brassington and Marsh 1998), and dysfunction of motor skills 
(Wei et al. 2010). At present, no adequate animal model for investigating 
mechanisms related to basal ganglia demyelination has been described. The basal 
ganglia represent sub-cortical nuclei interconnected with the cerebral cortex, 
thalamus, and brainstem which are implicated in a variety of functions such as motor 
control, cognition, emotion, and learning. The five individual nuclei that make up the 
primate basal ganglia along with their major subdivisions are the striatum (i.e. 
putamen and caudate nucleus), the external and internal segment of the globus 
pallidus, the subthalamic nucleus, and the substantia nigra (Bakker and Ludwin 
1987). The striatum is a heterogeneous mosaic of two neurochemically, 
developmentally, and functionally distinct compartments, i.e. the mu-opioid receptor-
enriched striosomes and the matrix (Miura et al. 2007; Pott et al. 2009; Sato et al. 
2008).” 
As a third brain structure we included the hippocampus formation (Norkute et al. 
2009) which is believed to be crucial for long-term episodic memory,, yet, its precise 
role still remains elusive (Bird and Burgess 2008; Burns and Young 2000; Kumaran 
and Maguire 2005): To the end, we found and discussed that “Cognitive impairment 
has been documented in MS (Brex et al. 2002; Potter 2002). A large number (40–
65%) of patients with established MS experience cognitive deterioration of variable 
severity (Summers et al. 2008; Tintore et al. 2006). Deficits in verbal and visual recall 
(DeLuca et al. 1998; Lazeron et al. 2005), speed of information processing (DeLuca 
et al. 2004), and aspects of executive function, particularly abstract reasoning (Foong 
et al. 1999), are commonly reported. Memory impairment is a striking feature within 
the spectrum of cognitive deficits in MS patients (Bobholz and Rao 2003; Rao et al. 
1991a; Rao et al. 1991b). The hippocampus comprises distinct regions, including the 
dentate gyrus and the literal hippocampus, which is subdivided into three fields, 
cornu ammonis (CA) regions 1-3 (Frotscher 1992; Frotscher et al. 1991; Leranth and 
Frotscher 1986; Lubbers and Frotscher 1987). Geurts et al. (2007) recently reported 
extensive hippocampus demyelination in MS patients in parallel with microglia and/or 
macrophage invasion and activation that strongly correlates with cognitive decline. 
This coincidence suggests that hippocampal demyelination is directly related to 
cognitive impairment. Despite the frequency and high functional impact, the 
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knowledge about effective strategies for managing cognitive impairment in MS is low. 
Research on therapeutic options for cognitive impairment in MS is still in the early 
stages. Available disease-modifying therapy strategies in MS only provide modest 
benefit for cognitive performance and improvement of cognitive dysfunction. As for 
nonpharmacological interventions that are based on cognitive rehabilitation, few 
studies have used an experimental approach, and in general, results have been 
disappointing. Therefore, further research strategies and animal models are needed 
in this area (Amato et al. 2006). Although novel insights into pathological processes 
related to MS gain in importance (Keegan et al. 2005; Lassmann 2008), the 
complexity of pathophysiological interactions are poorly understood (Norkute et al. 
2009).” 
In the cerebellum, the status of myelination and oligodendrocyte depletion was 
determined by histological staining and IHC for PLP and APC. Gene expression 
analysis of mature oligodendrocyte markers such as PLP and MBP was additionally 
conducted. Astrocyte and microglia responses were investigated by IHC, rt-RTPCR 
and quantification of both cell types. 
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4.2 Results 
4.2.1 Demyelination of distinct cerebellar areas 
Figures 1A/C/E and 1B/D/F show an anti-PLP stained cerebellum of a male control 
and cuprizone treated mouse, respectively. The effect of cuprizone (0.2%, 5 weeks) 
on demyelination was studied in different white and grey matter regions, namely the 
molecular layer (ML), the granular layer (GL), the pyramidal layer (PL), and the white 
matter layer (WM) of the cerebellar cortex (CCx), as well as the cerbellar marrow 
(CM) containing the rodent lateral cerebellar nucleus (LCN), medial cerebellar 
nucleus (MCN), and interpositos nucleus (IN). The regions are outlined in figure 1. 
Effect of cuprizone on myelination of these regions is shown in figures 1A (control 
animal) and 1B (cuprizone-treated) in an overview. Intact myelin in anti-PLP stained 
sections appears as dark fiber tracts. Cuprizone exposure resulted in a massive 
demyelination of the cerebellar marrow as detected by a loss of anti-PLP stained 
fibers in this region. Demyelination of the cerebellar marrow was mainly observed in 
all three cerebellar nuclei (figs. 1A-D). The surrounding area of the cerebellar nuclei, 
i.e. the white matter of the cerebellar marrow, was not affected by cuprizone 
treatment (fig. 1A/B). Interestingly, myelin sheaths of the cerebellar cortex including 
the molecular layer, the granular layer, the pyramidal layer and the white matter layer 
were also not affected (fig. 1E/F).  As shown in figure 1G, scoring of anti PLP-stained 
sections from zero to three revealed that the myelin status of cerebellar nuclei is 
significantly reduced by approx. 80% after the 5 weeks cuprizone challenge (control: 
3, cuprizone: 0.42±0.14, p<0.01).  
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Figure 1 Effect of cuprizone (5 weeks, 0.2%) on myelination of different cerebellar white and grey matter 
areas in male C57BL/6 mice. (A) shows anti PLP-staining of a control animal and gives and overview of the 
two principal regions included in this study. (B) shows anti-PLP staining of a mouse treated 5 weeks with 
cuprizone. The upper box in (A) indicates the cerebellar cortex region (CCx) including the molecular layer 
(ML), the pyramidal layer (PL), the garnular layer (GL) and the cerebellar white matter (WM) as detailed 
indicated in (E). The lower box in (A) indicates the cerebellar marrow containing the rodent cerebellar nuclei, 
namely the lateral cerebellar nucleus (LCN), medial cerebellar nucleus (MCN), and interpositos nucleus (IN), 
as detailed indicated in (B). (C) and (D) show the interpositus nucleus of a control and cuprizone treated 
animal, respectively, whereas (E) and (F) show the cerebellar cortex of a control and a cuprizone treated 
animal, respectively, in a higher magnification. Note profound demyelination in the rodent cerebellar nuclei, 
whereas, the cortical region is not affected. As shown in (G), quantitative assessment of cerebellar nuclei 
myelination revealed a significant reduction in myelin score by >95% compared to control (**p<0.01). (H) 
and (I) show quantitative analysis of MBP and PLP gene expression during 5 weeks of cuprizone treatment in 
the entire cerebellum.. Values were normalized against a housekeeping gene (HPRT) and expressed as % of 
controls (**p<0.01, and ***p<0.001 compared to controls; * p<0.05 3 weeks compared to 5 weeks). Scale 
bars: 200µm (A/B); 20μm (C-F). 
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For further quantification, real-time gene expression analysis of two marker proteins 
of mature oligodendrocytes (MBP and PLP) for the total cerebellum not containing 
the cerebellar peduncles was performed to obtain quantitative information about the 
time-dependent decline in oligodendrocyte myelin formation capacity after cuprizone 
exposure (0.2%, different time intervals). Quantification of MBP and PLP mRNA 
expression levels in the total cerebellum supports the above observation. As shown 
in figures 1H and I, both myelin marker genes decreased stepwise until week 3. First 
significant reductions (p<0.01) were already observed after 2 weeks cuprizone for 
MBP (30% compared to controls) and after 1 week for PLP (45% compared to 
controls). Levels of PLP further declined by approx. 70% compared to controls till 
week 5 (p<0.001). Levels of MBP declined till week 3 by approx. 70% compared to 
controls (p<0.001) whereas a partial recovery was detectable till week 5 (p<0.05). 
Concordantly with results obtained by anti-PLP immunohistochemistry, the number of 
mature oligodendrocyte cell bodies gradually decreased in areas of the cerebellar 
nuclei during the 5-weeks cuprizone exposure period (figs. 2A-C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Effect of cuprizone exposure (0.2%, 5 weeks) on the distribution of APC-positive oligodendrocytes 
in the cerebellar nuclei. (A) and (B) show anti APC-staining of a control and cuprizone treated animal in the 
rodent interpositus cerebellar nucleus, respectively. Arrows in (A) indicate APC-positive cells. Note the 
decline of mature oligodendrocyte cell bodies after 5 weeks of cuprizone exposure. (C) shows quantification 
of the number of APC-positive cells in the rodent interpositus cerebellar nucleus. Numbers of APC-positive 
cells are expressed as cells/mm2. **p<0.01 compared to controls. Scale bar: 20µm  
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Exemplarily, the quantitative evaluation of mature oligodendrocyte numbers in the 
interpositus nucleus is presented (fig. 2C). It reveals a significant (p<0.01) reduction 
of APC-positive cells (control: 709±12, cuprizone 5-weeks: 333±19). The medial and 
the lateral cerebellar nucleus exhibited a similar quantitative loss in APC-positive 
cells (quantification and picture not shown).  
 
4.2.2 Astrocyte and microglia responses during cerebellar demyelination 
In a next step, we analyzed astrocyte and microglia reactions in the affected 
cerebellar areas. All images and bars show results from the interpositus nucleus. 
However, the medial and the lateral cerebellar nuclei exhibited similar changes (data 
not shown). During cuprizone-induced demyelination, higher numbers of GFAP-
positive astrocytes are seen within the cerebellar nuclei and the surrounding 
cerebellar marrow (figs. 3B and D) compared to controls (figs. 3A and C). In addition, 
the morphology of astrocytes revealed thin cells only possessing a few short 
processes under control conditions (fig. 3C). In contrast, during cuprizone 
intoxication, astrocytes became hypertrophic and multipolar (fig. 3D). Furthermore, 
we observed a pronounced increase in astrocyte cell numbers in the CC and 
adjacent cortex that served as control regions (data not shown). Quantification of 
GFAP mRNA expression in the total cerebellum supports the above observation. 
GFAP induction was seen after 5 weeks (fig. 3 E, p<0.001). In order to further 
characterize astrocyte reaction and to precisely relate astrogliosis or to exclude 
hyperplasia, we have performed morphometric measurement of GFAP-positive cells 
in the areas of the cerebellar nuclei. First, the number of astrocytes per unit (mm2) 
increased significantly (p<0.001) until week 5 compared to controls (fig. 3F). Absolute 
numbers were 218±14 cells/mm2 (control) and 461±23 cells/mm2 (cuprizone). 
Furthermore, the average area occupied by an astrocyte was 13.5±12 µm2/cell 
(control) compared to 89±13 µm2/cell at week 5 (fig 3G). This hyperplasia reaction 
was highly significant (p<0.001). As shown in figs. 3A and B, such increase in GFAP 
positive cells was not visible in any investigated cerebellar cortex region.  
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IHC for Iba-1 to detect microglia/macrophages demonstrated that (i) microglia is 
uniformly distributed in the cerebellar marrow (fig. 4A and C) and (ii) intense increase 
of Iba-1-positive cells can be observed after 5 weeks of cuprizone exposure (figs. 4B 
and D) in and around the cerebellar nuclei. As shown in figure 4, an increase in Iba-1 
positive cell numbers is not evident in any investigated cerebellar cortex region. 
Microgliosis is evident between week 3 and 5 in the investigated regions. Absolute 
numbers were 82±21 cells/mm2 (control) and 2623±43 cells/mm2 (cuprizone) (fig. 
4E). This effect was highly significant (p<0.001).  
Figure 3 Effect of cuprizone exposure (0.2%, 5 weeks) on the distribution of GFAP-positive astrocytes (A-
D), the expression of GFAP mRNA (E), the number of GFAP-positive cells (F), and the astrocyte 
hypertrophy (G). (C and D) show the interpositus cerebellar nucleus in a higher magnification. After 5 
weeks of cuprizone treatment, a massive astrocytosis can be seen in and around the cerebellar nuclei. GFAP 
expression was maximally induced after 5 weeks (***p<0.001) compared to controls and 3-week treatment. 
At 5 weeks, astrocyte numbers increased from approx. 220 (control) to 460 cells/mm2 (cuprizone, 
***p<0.001) compared to controls. In addition, the volume occupied by a GFAP-positive cell increased 
from approx. 20 to 85 µm2/cell after cuprizone (***p<0.001). 50 cells were analyzed per experimental 
group. Scale bars: 200µm (A/B); 20μm (C/D). 
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Figure 4 Effect of cuprizone exposure (0.2%, 3 and 5 weeks) on the distribution of Iba1-
positive microglia/macrophages in the cerebellum (A-D) and the number of Iba-1-positive 
cells (E). (C and D) show the interpositus cerebellar nucleus in a higher magnification. After 5 
weeks of cuprizone treatment, a massive microglia/macrophage increase can be seen in and 
around the cerebellar nuclei. At 5 weeks, microglia/macrophage numbers increased from 
approx. 100 (control) to 2600 cells/mm2 (cuprizone, ***p<0.001) compared to controls. Scale 
bars: 200µm (A/B); 20μm (C/D). 
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4.3 Discussion 
One of the important criteria for the diagnosis of MS is the demonstration of white 
matter lesions in the brain (Polman et al. 2011). This type of white matter lesions is 
the major pathological hallmark of MS and disseminate in space and time. However, 
factors that contribute to clinical deterioration include grey matter lesions and axonal 
damage as well. Cuprizone was thought to mainly affect the CC white matter tract 
and the cerebellar peduncles (Matsushima and Morell 2001; Silvestroff et al. 2010). 
Grey matter lesions in the cerebral cortex of cuprizone treated mice have been 
described only recently (Skripuletz et al. 2008). In this Chapter, I present our data 
addressing the question whether the cuprizone model mimics the spatial 
dissemination of MS lesions. Regions included in this discussion are (i) the 
cerebellum (Groebe et al. 2009), (ii) the basal ganglia system (Pott et al. 2009), and 
(iii) the hippocampus (Norkute et al. 2009). The cerebellum is a well-known part of 
the brain affected by demyelinating events in both, MS (Gilmore et al. 2008; 
Kutzelnigg et al. 2007; Pokryszko-Dragan et al. 2008) and EAE. Concordantly, 
patients with MS frequently develop symptoms owing to cerebellar lesions, such as 
dysmetria leading to hand dexterity impairment. The cerebellum takes part in several 
motor functions through its influence on the motor cortex and corticospinal output. 
Furthermore, the cerebral cortex and the cerebellum are tightly interconnected by a 
large descending fiber system, the cerebro-ponto-cerebellar projections. Besides the 
superior cerebellar peduncles, other regions of the cerebellum are affected by 
cuprizone administration. The most striking feature of cerebellar demyelination is the 
intense affection of the cerebellar marrow containing the rodent cerebellar nuclei, 
namely the lateral cerebellar nucleus, medial cerebellar nucleus, and interpositos 
nucleus. This demyelination event can be demonstrated by staining myelin fibers and 
mature oligodendrocyte cell bodies. The cerebellar nuclei are the primary output 
targets of the cerebellum (Kleim et al. 1998). A vast amount of cortical and sensory 
information that converges onto the cerebellum is integrated by cerebellar Purkinje 
cells and subsequently conveyed to the neurons of the deep cerebellar nuclei. Those 
neurons further process this information and thus generate the major output of the 
cerebellum (Alvina et al. 2008). They are involved in a plethora of functions such as 
complex motor skill learning (Kleim et al. 1998; Sanchez-Campusano et al. 2007), 
modulating food intake behaviour, as well as other non-somatic functions by 
modulating the hypothalamus (Pu et al. 1995). In this model, demyelination of distinct 
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cerebellar cortical regions can not be detected, at least if conventional 
immunohistochemical techniques are used. This is in contrast to human MS 
pathology. In MS, the cerebellar cortex is a major predilection site for demyelination, 
in particular in patients with primary and secondary progressive MS. Cerebellar 
cortical demyelination occurs mainly in a band-like manner, affecting multiple folia (so 
called subpial lesions). The lesions are characterized by primary demyelination with 
relative axonal and neuronal preservation, although some axonal spheroids and a 
moderate reduction of Purkinje cells are present (Kutzelnigg et al. 2007). In our 
study, we were not able to show involvement of the cortical grey matter including the 
superficial molecular layer, the middle pyramidal cell layer, as well as the deep 
granular cell layer by conventional light microscopy or electron microscopy studies 
(Groebe et al. 2009). The white matter of the cerebellar cortex, however, displayed 
distinct minor myelin involvement, namely swelling of myelin sheath on the electron 
microscopy level (Groebe et al. 2009). We, therefore, have to conclude that 
cuprizone induced demyelination mimics well cerebellar deep grey matter 
involvement but not cerebellar cortex pathology of MS. 
In the basal ganglia which are also frequently affected in MS pathology (Brownell and 
Hughes 1962; Hasan et al. 2009; Henry et al. 2008; Nociti et al. 2008; Pirko et al. 
2007), a medial-to-lateral gradient of demyelination with more severe effects in the 
lateral striatal complex was observed (Pott et al. 2009). This region-specific effect 
appears to be the result from diminished local microglia activation but also from 
higher numbers of oligodendrocyte precursors which might contribute to 
simultaneous remyelination during myelin destruction. These data support the view 
that demyelination in the basal ganglia follows a medio-lateral distribution without 
stopping at anatomical borders. Demyelination was highly reproducible and 
predictable with respect to the temporal and spatial occurrence. This makes the 
cuprizone mouse model attractive for investigating the underlying mechanisms of 
demyelination and remyelination (Matsushima and Morell 2001) in this brain region 
(Pott et al. 2009). Interestingly, the observed preferential myelin loss of laterally-
located white matter tracts (within striosomes) does not apply for axons located in the 
grey matter (within the matrix). Microglia accumulation was also more pronounced in 
the lateral part and might therefore contribute for preferential demyelination of the 
lateral orientated striosomes (Pott et al. 2009). Mechanisms related to white and grey 
matter demyelination within this brain complex appear to differ.  
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The hippocampus, located in the medial temporal lobe, is part of the forebrain and 
integrated into the limbic circuitry. This subcortical structure appears to be crucial for 
cognitive performance and plays a major role for short term memory and spatial 
navigation (Bird and Burgess 2008). Cognitive impairment is a well-known 
phenomenon described for MS (Brex et al. 2002; Potter 2002). In MS patients, 
demyelination lesions have been seen in pathological specimens, and areas of signal 
abnormality have been detected within the hippocampus by double inversion 
recovery MRI (Geurts et al. 2007; Norkute et al. 2009; Vercellino et al. 2005).  
We recently presented findings demonstrating that feeding with cuprizone causes a 
highly reproducible and severe but distinct demyelination within the hippocampus 
grey and white matter. Demyelination displayed a gradual time course between 3 and 
7 weeks and was complete after 5 to 7 weeks (Norkute et al. 2009). Both white 
matter tracts of the hippocampus and grey matter areas (such as the stratum 
lacunosum moleculare containing the perforant path, the hilus of the dentate gyrus 
and the stratum pyramidale in CA-2/3), are strongly affected by cuprizone treatment. 
Demyelination in grey matter structures was more prominent and severe compared 
with white matter (Norkute et al. 2009). Hippocampal demyelination in white matter 
tracts was only seen in the medial alveus and the dorsal hippocampal commisure, 
whereas the fimbria and the lateral alveus were not affected. Although no clear-cut 
answer to this phenomenon can be given at present, a possible underlying reason 
could be differences in regional hippocampal blood supply (Pereira et al. 2007). 
Diversity among hippocampus subfield vascularisation has been documented (Grivas 
et al. 2003; Lovick et al. 1999). A recent study further suggests that local microglia 
response is implicated in this scenario (Kipp et al. 2011).  
Besides regional differences in demyelination pattern, a second important outcome of 
our study was that cuprizone application results in astroglial proliferation and/or 
migration toward the injured area. We described astrogliosis which is due to 
increased numbers of astrocytes on one hand and hypertrophic astroglial responses 
on the other hand. Both effects, finally, result in an increased area occupied by 
astrocytes in demyelinated regions (Groebe et al. 2009; Norkute et al. 2009; Pott et 
al. 2009). Astrocytes may play an active role during degeneration and demyelination 
by promoting inflammation, damage of oligodendrocytes and axons, and glial 
scarring, but might also be beneficial by creating a permissive environment for 
remyelination and oligodendrocyte precursor migration, proliferation, and 
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differentiation (Markus et al. 2000). The same is true for microglia cells. Despite 
intense astrocytosis, demyelinated areas usually display intense accumulation of 
microglia, either by local proliferation and/or invasion. The role of both microglia and 
astrocytes during acute demyelination in the cuprizone model is currently under 
intense investigation by our group and is briefly discussed in the main discussion of 
this work. In summary, the first part of this thesis clearly shows that certain aspects of 
MS, such as grey matter pathology (Kidd et al. 1999), dissemination in space (Shaw 
et al. 2009) and brain intrinsic inflammation (Hemmer et al. 2002) are closely 
mirrored in the cuprizone model. 
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5. Chapter II 
Corticosteroids during de- and remyelination in the 
cuprizone animal model 
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5.1 Introduction 
Corticosteroids (CS) are regularly used for the tretament of MS, since they can 
decrease the inflammatory response by dampening the inflammatory cytokine 
cascade, inhibiting the activation of T-cells, decreasing the extravasation of immune 
cells into the CNS, facilitating the apoptosis of activated immune cells, and, indirectly, 
by decreasing the cytotoxic effects of nitric oxide and TNF-α (Sloka and Stefanelli 
2005).  
Demyelination is still a characteristic entity for the pathology of MS but it has become 
increasingly apparent in recent years that substantial axonal and neuronal loss are 
equal important features (Baracskay et al. 2002; Geurts et al. 2007). The loss of 
nerve’s myelin sheath is not a definitive condition in demyelinating disorders. 
Progenitor cells of the oligodendrocyte lineage, a cell population which is responsible 
for myelination during development, can be (re)-activated and give rise to new 
myelinating mature oligodendrocytes. This endogenous repair process is termed 
”remyelination”. Remyelination is the best-documented and most robust example of 
tissue repair in the human CNS. Approximately 40% of post-mortem MS tissues 
demonstrate signs of remyelination which can occur early and late during the course 
of MS (Franklin and Ffrench-Constant 2008; Irvine and Blakemore 2008; Patrikios et 
al. 2006). This process is important for axonal protection in demyelinating disorders. 
Remyelination is believed to restore the structural integrity of the axon-myelin unit 
and axonal conduction properties that are lost following demyelination (Beck et al. 
1993; Halliday 1981). It is unresolved why in some patients remyelination is 
widespread while in others, it is sparse. The increasing importance of axonal damage 
and loss as the pathological basis for progressive loss of function demands a better 
understanding of the remyelination processes in MS and possible reasons for its 
failure. In this context a better understanding of steroidal interference with 
endogenous remyelination processes is essential. Beyond its anti-inflammatory 
function, previous reports have linked CS-mediated signalling with impaired (Chari et 
al. 2006; Triarhou and Herndon 1986) as well as accelerated (Pavelko et al. 1998) 
repair process after experimentally-induced demyelination (i.e. remyelination). 
OPC express glucocorticoid (GC) receptors (Bohn et al. 1991). Direct interactions of 
CS and cells of the oligodendrocyte lineage have been reported (Barres et al. 1994). 
Methylprednisolone (MP) reduced TNF-α-induced nitric oxide release in OLN93 cells 
(Holzknecht and Rohl 2010) and protected oligodendrocytes against AMPA-induced 
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excitotoxicity in vitro (Sun et al. 2010; Xu et al. 2009). There are additional studies 
suggesting that CS influence OPC maturation and/or differentiation (Barres et al. 
1994; Joubert et al. 2010; Kumar et al. 1989). During glial differentiation, the 
expression of 2',3'-cyclic-nucleotide 3'-phosphodiesterase (CNPase) was induced by 
dexamethasone (Dex) treatment, a potent synthetic glucocorticoid-receptor agonist 
that stimulates oligodendroglial differentiation and myelination during the early phase 
of myelination in reagregating forebrain cultures (Almazan et al. 1986). Dex had a 
stimulatory or inhibitory effect on differentiation depending on the developmental 
stage of the cells (Almazan et al. 1986). In co-cultures of Schwann- and neuronal 
cells, Dex accelerated the time of initiation and enhanced the rate of myelin synthesis 
(Chang et al. 2002).  
The most common MS animal model, EAE, is a mainly lymphocyte-driven model, 
which makes it difficult to distinguish between direct CS effects on remyelination and 
indirect effects due to CS immuno-modulation. Therefore, we used the toxic, non 
auto-immune driven cuprizone mouse model which induces a highly reproducible 
demyelination of distinct brain regions, among the CC (Acs et al. 2009; Clarner et al. 
2010; Groebe et al. 2009; Pott et al. 2009). Spontaneous repair occurs after removal 
of the toxin from the diet, allowing investigation of spontaneous repair mechanisms 
such as OPC differentiation and restoration of myelin, as well as effects of 
pharmacological interventions on these processes (Kipp et al. 2009). Since no 
invasion of peripheral T-cells takes places, this model additionally allows studying 
direct steroidal effects on brain intrinsic inflammatory responses, such as the 
accumulation of microglia and astrocytosis. 
In the present study, we aimed to analyze whether CS interfere with spontaneous 
endogenous remyelination during progressive disease stages where lymphocyte 
infiltration is less distinct. Furthermore, using primary astroglia and OPC cultures, we 
attempted to analyze cell-specific effects of CS that might be related to the 
remyelination capacity. 
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5.2 Results  
5.2.1 Glucocorticoids accelerate spontaneous differentiation of cultured OPC 
For studying the influence of GC on oligodendroglial differentiation in vitro, we used 
an OPC culture system which displays spontaneous differentiation within several 
days (5-7 days) under defined medium conditions (Richter-Landsberg and Vollgraf 
1998). In a first set of experiments, we analyzed the kinetics of OPC differentiation. 
As shown in figure 5, OPC spontaneously differentiate within several days in serum-
free medium supplemented with insulin, transferrin, and sodium selenite. 
Differentiation is reflected by a gradual increase in the expression of the myelin 
marker genes MBP, PLP and CNPase (figures 5A/D). Induction of myelin markers is 
paralleled by morphological maturation (figure 5B). After one day in culture, cells 
display a typical bipolar OPC morphology with long extending processes. After 5 
days, cells are multipolar and show highly-branched processes indicating 
differentiation (Barres et al. 1994; Zakzanis 2000). Additional experiments revealed 
that maturation progresses till day 7, both on the morphological and gene-expression 
level (data not shown). In order to assess the influence of GC on OPC differentiation, 
cells were exposed for 5 days (subtotal differentiation) to Dex or MP. Figures 6A/C 
depict that both CS accelerated OPC differentiation in vitro. Expression analysis of 
MBP and PLP revealed significantly higher mRNA transcript levels in Dex- and MP-
treated cultures. For Dex, ~2-fold and 3-fold induction was found for MBP and PLP, 
respectively (compared to controls). For MP, ~1.5-fold and 2-fold induction was 
observed for MBP and PLP, respectively (compared to controls). In line with these 
findings, Western-blot analysis revealed higher CNPase protein levels in Dex-treated 
groups as shown in figure 5D. These results convincingly show that both CS 
positively interfere with the endogenous differentiation program of OPC.  
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5.2.2 CS treatment regulates growth factor expression in astrocytes 
There is evidence that the effect of CS on OPC differentiation depends on the 
presence or absence of mitogens such as PDGF-αα and FGF2 (Barres et al. 1994). 
Since astrocytes are a well-known source of certain growth factors that are able to 
modulate remyelination processes, we investigated CS effects on growth factor 
mRNA expression. PDGF-αα and FGF2 were included in the analysis due to their 
well known promotion of OPC proliferation. Expression levels of IGF1 were analyzed 
because this growth factor is well-known to promote OPC maturation. 
Labelling for GFAP and CS receptor showed that virtually all cells in the applied 
primary astrocyte culture system expressed CS receptors (figure 6A). Expression 
levels are expressed as a ratio of those factors which promote OPC proliferation 
(PDGF-αα and FGF2) to IGF1 which promotes maturation. A high ratio indicates a 
proliferating, anti-maturating effect, while a low ratio indicates a maturating influence 
on OPC. Treatment with Dex for 24 h significantly increased the ratio of PDGF-αα 
Figure 5 MBP and PLP mRNA expression levels in primary oligodendrocyte cultures determined by rtRT-PCR 
are shown in (A) and (B), respectively. Results of gene expression analysis are normalized against a 
housekeeping enzyme (GAPDH) and expressed as percentile of controls. Representative phase contrast views of 
cultured oligodendrocytes are presented in (C). Results of anti-CNPase Western blotting experiments are 
presented in (D). ß-actin was used as loading control. Note the increase of oligodendrocyte differentiation-related 
genes (i.e. MBP and PLP) during a 5 days culture period which is potentiated by GC treatment. Scale bars in (B): 
10 µm, * P < 0.05, ** P < 0.01, *** P < 0.001 compared to controls.   
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and FGF2 to IGF1 expression in primary astrocytes cultures (promoting a 
premature/proliferative stage of OPC). Expression levels of investigated genes were 
additionally normalized against a housekeeping gene (HPRT), and control values 
were set as 1. These data are given in figure 6B. Treatment with CS caused a 
significant induction of FGF2 and PDGF-αα, whereas IGF1 mRNA levels were 
decreased by CS treatment. Figure 6D shows a representative western blot for FGF2 
protein, confirming that mRNA changes are paralleled by respective protein level 
changes after CS administration. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 Ratio of expression levels of fibroblast growth factor 2 (FGF2) or platelet-derived growth factor-αα 
(PDGF-αα) to insulin-like growth factor-1 (IGF1) in Dex-exposed astrocytes and expression of glucocorticoid 
receptors in cultured murine GFAP-positive astrocytes (A). Gene expression levels of FGF2, PDGF-αα, and IGF-1, 
normalised against the housekeeping gene hypoxanthin-guanin-phosphoribosyltransferase (HPRT), is presented in 
(B). In (C), ratio of expression levels of proteolipid protein (PLP) and myelin basic protein (MBP) to platelet-
derived growth factor receptor-α (PDGFR-α) in cultured oligodendrocytes after treatment with Dex or Dex plus 
growth factors (GF) PDGF-αα and FGF2 is shown. Results are expressed as percentage of controls at day 5. A 
representative anti-FGF-2 western-blots in Dex-treated astrocytes is shown in (D).  * P < 0.05, ** P < 0.01, *** P < 
0.001 compared to controls. 
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5.2.3 Acceleration of Dex-mediated OPC differentiation is abolished by FGF2 
and PDGF-αα 
Our data obtained with astroglia cultures clearly show that those factors which 
promote OPC proliferation are induced by CS, whereas pro-maturating factors are 
reduced, respectively. We assumed that direct effects of GC on OPC maturation 
might be modulated by GC-induced release of FGF2 and PDGF-αα. Therefore, we 
analyzed the influence of Dex alone or in combination with both growth factors on 
MBP and PLP mRNA expression in isolated OPC cultures. As expected, the ratio of 
MBP or PLP (preferentially expressed in mature oligodendrocytes) to PDGFRα 
(preferentially expressed in OPC) is low in OPC cultured for one day. This ratio 
increases during spontaneous differentiation until day 5 (fig. 6C), reflecting OPC 
differentiation. Dex treatment potentiated this ratio increase. In contrast, the 
application of growth factors completely prevented OPC differentiation, and Dex was 
no longer able to induce OPC differentiation. These data convincingly show that the 
modulation of astrocytic growth factor release can interact with direct steroidal effects 
on OPC differentiation.  
 
5.2.4 MP treatment interferes with endogenous myelination capacity after 
cuprizone-induced demyelination 
Our in vitro data imply that corticosteroids directly interfere with OPC maturation 
which might be modulated indirectly by growth factors released by astrocytes. 
Therefore, interference of MP treatment with spontaneous repair mechanisms that 
are crucial for remyelination was tested after acute cuprizone-induced demyelination. 
Figure 7A illustrates the experimental design of our in vivo experiments. To assure 
sufficient systemic application of MP and to rule out that cuprizone feeding induces 
activation of the hypothalamo-hypophyseal-adrenal axis, serum levels of ACTH were 
determined by ELISA prior to scarification. The application of MP caused a significant 
reduction of ACTH serum levels compared to placebo-injected controls (fig. 7B). No 
reduction was found in cuprizone + vehicle-treated animals compared to controls. 
Myelin index staging (both, manually and via densitometry) and quantification of 
APC-positive oligodendrocytes were performed in experimental groups. Figure 7C 
shows the results of PLP reactivity staging. Representative anti-PLP stained sections 
of the medial CC are presented in figure 7D. As expected, 5 weeks cuprizone feeding 
decreased the myelination index of the CC by ~50%. This was paralleled by a 
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significant reduction of APC-immunoreactive oligodendrocyte numbers (fig. 7E). After 
9 days recovery, PLP staining intensity was unchanged in placebo-treated animals 
whereas demyelination progressed in MP-treated mice. These results indicate the 
suppression of early remyelination events after cuprizone-induced acute 
demyelination by systemic MP application. Spontaneous myelin recovery was evident 
after 21 days in PLP-stained sections (group IV). The intensity of PLP 
immunoreactivity was significantly lower in MP-treated (group VI) compared to 
placebo-treated animals (group IV). The re-appearance of APC-positive 
oligodendrocytes during early (9 days) and intermediate (21 days) endogenous 
remyelination was not affected by MP treatment. Additionally, we determined the 
density of PLP-stained CC on binary-converted pictures and found comparable 
results. 
 51
 
Figure 7 Experimental set-up of animal experiments is shown in (A). ACTH levels determined by ELISA in the 
serum of treated and untreated animals are shown in (B). Myelination index determined by staging PLP-stained 
sections is shown in (C). In (D), representative pictures of IHC for PLP of the medial CC are shown for groups I, 
II, IV and VI. Quantification of APC-positive oligodendrocytes within the CC is shown in (E). Placebo-treated 
mice showed no reduction in ACTH-serum levels compared to controls, whereas MP-treated animals displayed 
significant reduction. Note that recovery of anti-PLP staining intensity of the CC is significantly impaired in GC-
treated animals after 21 days recovery. Reappearance of APC-positive cells is not affected by GC treatment. * P<  
0.05, *** P < 0.001.  Scale bar: 50 µm.  
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5.2.5 MP treatment does not affect microglia and astrocyte cell numbers during 
endogenous remyelination 
We have further analyzed the effect of MP on the presence/absence of microglia and 
astrocytes in the CC by IHC during the remyelination period using the pan-
macrophage/microglia marker Iba1 and the astrocyte marker GFAP. As shown in 
figure 8A, the number of microglia was significantly lower 9 days after cuprizone-
induced demyelination (groups III) compared to the acutely demyelinated CC (group 
II). No further reduction was observed until day 21. In contrast, the number of GFAP-
positive astrocytes remained at high levels during early and intermediate 
remyelination (fig. 8B). As demonstrated, kinetic changes of microglia and astrocyte 
counts were not affected by MP treatment. 
 
 
 
 
 
 
5.2.6 Effect of CS on thyroid hormone plasma levels 
Thyroid hormones are unequivocally playing important roles during remyelination 
(Calza et al. 2005; Fernandez et al. 2004; Franco et al. 2008). Since CS are known to 
interfere with thyroid hormone levels (Haugen 2009; Nicoloff et al. 1970), we 
measured total T3 serum levels of experimental animals by solid phase competitive 
ELISA-analysis. Cuprizone treatment did not influence basal T3 serum levels after 5 
weeks (fig. 9). Remyelinating mice displayed slightly increased T3 serum levels (P = 
0.075 compared to controls) after three days of recovery. MP treatment during 
remyelination had no significant influence on T3 serum levels (P = 0.095, 3 days 
recovery MP-treated vs. 3 days recovery NaCl). 
Figure 8 Results of Iba1-positive microglia (A) and GFAP-positive astrocytes (B) quantification in the CC is 
shown. Results are expressed as cell numbers/mm2. Note that no significant difference in cell numbers could 
be observed in MP-treated animals compared to placebo controls for both cell types. *** P < 0.001  
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Figure 9 Quantification of T3 serum levels by solid phase competitive ELISA analysis is shown as scatter 
blot. Data are expressed as ng/ml. No significant decrease in the total amount of T3 could be found in 
MP-treated animals when compared to placebo-treated controls (n = 5). 
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5.3 Discussion 
Clinical treatment of MS is to date based on the assumption arising from preclinical 
and animal studies that the suppression of autoimmune reactions can positively 
modify disease pathogenesis and neuronal damage. A further important goal is to 
reduce the number of relapses or to decrease their impact on the accumlation of 
neurologic symptoms. Beyond that, the promotion of tissue repair to reverse 
neurologic symptoms is another important aim (Compston and Coles 2002). Starting 
in 1950s, GC are routinely used as therapeutic instrument for MS treatment due to 
their potent anti-inflammatory effects. Today, a widely used treatment option is the 
administration of high doses of GC. GC are very helpful tools to effectively manage 
acute relapses in MS (Keegan and Noseworthy 2002). Typically, the drug is supplied 
intravenously for 3–5 days. This treatment can additionally be tapered by oral CS by 
several days up to weeks. CS act through the classical CS receptor, leading to an 
inhibition of the synthesis of pro-inflammatory cytokines and cell surface molecules 
required for immune function and modulation (Sloka and Stefanelli 2005). Despite 
their widespread use, not much is known about the effects of CS treatment on 
regenerative processes in the adult CNS. The possible mechanisms by which CS 
might influence the most important repair process in MS, the remyelination process, 
are poorly understood.  
It has been postulated that GC are able to interfere with the course of MS. This class 
of steroid hormones might prevent new exacerbations and, therefore, modify the 
natural history of MS by reducing the accumulation of neurologic symptoms and 
disability.  
Patients suffering of first episode optic neuritis that were treated with MP showed 
lower conversion rates towards definite MS (Beck et al. 1993). Zivadinov and 
colleagues presented data in 2001 that the treatment with pulses of i.v. MP in 
relapsing-remitting MS patients slowed the development of T1 black areas. They also 
showed that whole-brain atrophy and disability progression can be prevented or 
delayed by CS (Zivadinov et al. 2001). MS patients that were treated with high dose 
intravenous CS during six months post partum might have a reduced risk of an acute 
relapse after childbirth (de Seze et al. 2004).  
Studies concerning the effects of long-term GC treatment in MS show a substantial 
heterogeneity between the different studies (recently reviewed by Ciconne et al. 
(2008)),  
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For example, the risk of disability progression was reduced by i.v. application of high 
dose MP in relapsing remitting MS after 5 years (Zivadinov et al. 2001), whereas low 
dose and orally-applied prednisolone did not lead to reduced risk after 18 months 
treatment (Miller et al. 1961). Because of this heterogeneity and the lack of further 
studies, the routine use of long-term GC treatment cannot be justified at the moment. 
When it comes to CS effects on repair mechanisms in the CNS, studies on toxic 
demyelination animal models (lysolecithin-induced spinal cord demyelination) yielded 
conflicting results. On one hand, MP treatment accelerated spontaneously occurring 
repair/remyelination that was paralleled by reduced invasion of macrophages 
(Pavelko et al. 1998). On the other hand, an earlier study using the same lesion 
model demonstrated a delay in remyelination of rats treated with Dex (Triarhou and 
Herndon 1986). In a different toxic demyelination model (CNS injection of ethidium 
bromide into the rat spinal cord), Dex treatment led to delayed remyelination that 
occurred independently from the colonization of the lesion with PDGFRα positive 
OPCs (Chari et al. 2006).  
In the above mentioned animal models, a disruption of the blood-brain-barrier can be 
observed. We, therefore, have chosen the cuprizone animal model for our study, 
since it allows to investigate the impact of CS on the remyelination process that 
follows acute toxic demyelination without interference of invading peripheral blood 
cells (due to an intact BBB) (Bakker and Ludwin 1987; Kondo et al. 1987; Liu et al. 
2010)  In our in vitro approaches, we aimed to study direct CS effects on OPC and 
astrocyte cultures.  
We could demonstrate an acceleration of OPC maturation by CS in vitro (Clarner et 
al. 2011b). Similar effects have been reported by other groups (Barres et al. 1994; 
Joubert et al. 2010; Kumar et al. 1989). It is well-known, that OPC express GC 
receptors (Bohn et al. 1991). Direct interactions of CS and cells of the 
oligodendrocyte lineage have also been reported (Barres et al. 1994). Pathways that 
can be directly influenced by CS include the TNF-α-induced nitric oxide release (as 
shown for OLN93 cells) (Holzknecht and Rohl 2010). CS are also protective for 
oligodendrocytes which were exposed to AMPA-induced excitotoxicity in vitro (Sun et 
al. 2010; Xu et al. 2009). However, these direct CS effects upon OPC could be 
modulated by indirect stimuli, e.g. modulated growth factor release by astrocytes in 
vivo. Several growth factors have been shown to interfere with OPC proliferation and 
maturation and, in consequence, might modulate endogeneous remyelination. OPC 
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differentiation and proliferation is under the control of PDGFRα and FGF2 receptor 
signalling in vitro and in animals (Bogler et al. 1990; McKinnon et al. 1991; Pringle et 
al. 1989; Raff et al. 1983). IGF1 represents another important member of the TGFß 
family of growth factors and has been shown to induce myelination in vitro and in 
vivo. This factor also exhibits protective effects on mature oligodendrocytes under 
neuropathological challenges (D'Ercole et al. 1996; Mason et al. 2000). Since 
astrocytes are well-know to be an important source of various growth factors (Acs et 
al. 2009; Braun et al. 2009), we decided to investigate CS-induced changes in the 
growth factor expression pattern of these cell type. 
Our results clearly argue for the possibility that direct steroidal effects on OPC can be 
modulated by astrocyte-derived growth factors. As shown, those growth factors which 
have been described to participate in OPC proliferation (i.e. PDGF-αα and FGF2) are 
induced, whereas pro-maturating growth factors (such as IGF1) are slightly 
repressed by GC treatment, respectively (Clarner et al. 2011b). Comparable results 
have been recently reported by Chesik and De Keyser who found a decrease in the 
expression of IGF1 as a response to Dex treatment in both astrocytes and OPC 
(Chesik and De Keyser 2010).  
We performed a preliminary gene expression study using cuprizone-treated animals 
that were allowed to recover for three days and were treated either with MP or a 
placebo. Both investigated pro-proliferating growth factors (PDGF-αα and FGF2) 
were found to be induced by MP treatment, whereas IGF1 transcrips were slightly 
repressed. This is in line with our previous in vitro findings. We might speculate from 
these observations that the GC-mediated release of PDGF-αα and FGF2 from 
astrocytes in parallel with an inhibition of astrocytic IGF1 secretion impairs direct 
effects on OPC (i.e. acceleration of the endogenous maturation program) (Clarner et 
al. 2011b).  
In vitro, we could show that the presence of PDGF-αα and FGF2 in the OPC culture 
medium completely antagonizes both spontaneous as well as GC-induced OPC 
maturation. Astrocytes might not be the only cell type that shows CS-induced 
changes in the growth factor release. A feedback mechanism of the OPC 
differentiation signalling cascade might exist, since Dex could interfere with OPC 
growth factor release as well (Chesik and De Keyser 2010). OPC-derived IGF1 could 
promote OPC differentiation, unless suppressed by CS.  
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Results from our in vitro studies further suggest that the net effect of complex cell-cell 
interactions and steroidal interference with these pathological processes results in 
impaired remyelination (Clarner et al. 2011b).  
For several reasons, we decided to use the cuprizone model to study the impact of 
GC treatment on spontaneous endogenous remyelination properties. As already 
mentioned above, no disruption of the BBB takes place in the cuprizone model 
(Bakker and Ludwin 1987; Kondo et al. 1987). Therefore, no invasion of peripheral 
immune cells occures (Liu et al. 2010). Because of these characteristics, the 
cuprizone model allows us to investigate direct interference of CS with remyelination. 
Second, removal of the toxin from the chow leads to spontaneous rapid remyelination 
within a matter of weeks (Clarner et al. 2011b; Irvine and Blakemore 2006; Kipp et al. 
2009). Third, changes of growth factor expression levels in response to cuprizone 
intoxication have been investigated (unpublished data from our group) and showed a 
significant induction of IGF1 that remained high for several days after removal of the 
toxin from the diet. With respect to FGF2 and PDGF-αα mRNA levels, we found only 
a slight increase of both transcripts after 5 weeks of cuprizone feeding. Transcript 
levels rapidly decreased to the level of control animals when cuprizone was removed 
from the diet. Taken together, the cuprizone model reflects several aspects of the 
situation in vitro and thus simplifies comparison of in vivo and in vitro results (Clarner 
et al. 2011b).  
Endogeneous CS play an important role during myelination in CNS development 
(Gumbinas et al. 1973; Redzic et al. 2005) but repeated exogenous CS 
administration has been shown to result in an impaired  CNS development (Dunlop et 
al. 1997; Raschke et al. 2008). However, in the adult CNS and especially during 
pathological and inflammatory events, CS actions might substantially differ from 
those observed during development. Our in vitro results could be interpreted as a 
positive interference of CS with the progression of the intrinsic differentiation program 
which leads to an acceleration of myelin marker gene expression in this cell culture 
system. These direct effects on OPC differentiation suggest pro-myelinating effects of 
CS in a local environment that facilitates myelination (Clarner et al. 2011b). 
Contrariwise, accelerated differentiation might have a negatively impact on repair 
processes, since there is a need to synergize with other processes (e.g. those 
associated with inflammation) (Franklin and Ffrench-Constant 2008).  
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The different mechanisms underlying steroidal interference with OPC maturation 
need further investigation. CS have recently been shown to modify the histone 
acetylation status in natural killer cells, thereby reducing promoter accessibility 
(Krukowski et al. 2010). Effective remyelination requires deacetylation of 
nucleosomal histones, thus executing this complex transcriptional program during 
OPC differentiation (Shen et al. 2008) might be representing one of the CS-
associated mechanisms.  
One might speculate, that CS cause a reduction and/or disappearence of astrocytes 
and microglia during remyelination. However, numbers of both cell types were not 
reduced in MP-treated animals. This does not necessarily argue that pro-
inflammatory properties are not affected by MP because absolute cell numbers do 
not reflect cellular activity (Clarner et al. 2011b). This assumption is supported by 
data coming from another ongoing project. In this study, we were able to show that 
Dex treatment does not interfere with cuprizone-induced demyelination and 
concomitant glia cell activation (unpublished data). It appears that GC are powerful in 
dampening the peripheral immune response but lack efficacy in modulating brain 
intrinsic inflammatory pathways when the BBB is not affected.  
As a further mechanism that could explain the observed impaiment of remyelination 
by CS, interference with thyroid hormone plasma levels should be considered. The 
thyroid hormones T3 and T4 are thought to play important roles in the activation of 
OPC, remyelination, and neuronal protection (Fernandez et al. 2004; Franco et al. 
2008; Harsan et al. 2008). In cuprizone-treated remyelinating mice and rats, T3 
supplementation led to increased numbers of oligodendrocytes (Olig2+ cells), 
enhanced remyelination, and improved clinical symptoms (Franco et al. 2008; Harsan 
et al. 2008). In an autoimmune rat MS model (EAE), T4 supplementation led to 
improved remyelination, most likely via stimulating endogenous OPCs (Fernandez et 
al. 2004). Since CS are known to be able to suppress thyroid stimulating hormone 
secretion (Nicoloff et al. 1970; Wilber and Utiger 1969), we assumed that reduced 
levels of plasma thyroid hormones might contribute to the negative net effect of CS 
on remyelination in the cuprizone animal model. Although our experimental design 
cannot completely rule out this possibility, we consider this mechanism to be unlikely, 
since we only observed a marginal increase of plasma T3 in the spontaneous 
remyelination group. Additionally, CS treatment did not lead to hypothyroidism but the 
animals showed T3 serum levels comparable to controls (Clarner et al. 2011b).  
 59
In conclusion, we provide further evidence that exogeneous CS might impair 
reparative processes in the CNS. Our results additionally indicate that beneficial 
steroidal effects during CNS inflammation have to be balanced against possible 
remyelination-inhibiting effects in MS. 
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6. Chapter III 
The cuprizone model as a tool to study glia-derived 
amyloid precursor protein function 
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6.1 Introduction  
The role of amyloid precursor protein (APP) has been intensely studied under 
pathological and non-pathological conditions in the brain. The metalloprotein APP is 
abundantly and ubiquitously expressed in many cell types and spans membranes in 
the endoplasmic reticulum, trans-Golgi, and the cell surface (Cahill et al. 2009). Its 
abnormal proteolytic processing is associated with Alzheimer’s disease (Senechal et 
al. 2006). Depending on the secretase cleavage, different fragments of APP are 
produced. APP cleavage by β- and γ-secretase generates the pathogenic Aβ peptide 
that aggregates to form the main component of amyloid plaques during Alzheimer’s 
disease. Alternatively, processing of APP by the α-secretase prevents the formation 
of Aβ peptides and leads to secreted APP-α (sAPP) release in the so called non-
amyloidogenic processing pathway (Senechal et al. 2006). sAPPs are known to have 
neurotrophic or neuroprotective properties (Lee and Wurtman 2000; Thinakaran and 
Koo 2008).  
Besides neurons, astroglia and microglia cells are potential sources of APP within the 
healthy and diseased brain. The glial isoforms of APP consist of 770 or 751 amino 
acids compared to the 695 amino acid isoform predominantly found in neurons 
(Senechal et al. 2006). APP 770 was described to be more amyloidogenic than APP 
695 in cultured mouse astrocytes and an increased immunoreactivity for glial-derived 
APP was related to higher plaque density in AD brains (Lee and Wurtman 2000; 
Zhan et al. 1995). Neuronal derived APP was in the focus of most studies conducted 
so far. Far less is known about the role of astroglia derived APP. The presence of 
APP-positive astrocytes has been described in different experimental cerebral 
ischemia models (Banati et al. 1995b; Kalaria et al. 1993; Stephenson et al. 1992). 
Furthermore, it has been demonstrated that activated astrocytes express APP at high 
levels in MS lesions (Gehrmann et al. 1995). Induced APP expression was also 
reported within EAE foci. These results suggest a role of APP expression by brain 
resident inflammatory cells as a response to tissue damage or injury.  
In the present study, we investigated the induction and accumulation of APP within 
the acutely demyelinated CC. Cellular co-localization of APP with glial markers was 
achieved by double-immunofluorescence labelling. The general expression pattern 
was analyzed by RT-PCR and Western blotting. Neonatal mouse astroglia cultures 
were employed to study the APP responsiveness of astrocytes to different toxic 
factors.   
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6.2 Results 
6.2.1 Astrocytes express APP in the CC of cuprizone-treated mice  
After 5 weeks cuprizone treatment, demyelination can be detected within all parts of 
the CC after 5 weeks of cuprizone treatment indicated by a loss of PLP-reactive 
fibres. To study expression of APP in the demyelinated CC, IHC was performed 
using anti-APP antibodies. As shown in fig. 10B, high numbers of APP-positive cells 
with an astrocyte-like morphology are detectable in the CC after 5 weeks cuprizone. 
In contrast, no APP immunoreactivity was observed in control animals (fig. 10B). Due 
to the characteristic morphology, we assumed that APP expression can be allocated 
to (activated) astrocytes. Immunofluorescence double-labelling for GFAP and APP 
and confocal laser microscope analysis revealed that APP is exclusively present in 
astroglia (fig. 10C). APP shows an overlapping cellular distribution with GFAP. Both 
proteins are mainly located in the cytoplasm and cellular processes sparing the 
nuclear compartment. Notably, no other cell types, such as Iba-1 positive microglia 
cells, expressed APP within the CC, although microgliosis is apparent within the 
demyelination region (fig. 10A). 
 
6.2.2 APP gene and protein expression in the CC of cuprizone-treated mice 
As shown in fig. 10A, APP mRNA was low in control animals. In contrast, a time-
dependent induction of APP expression was observed as early as one week 
cuprizone treatment. PCR analysis for GFAP mRNA revealed a similar pattern of 
expression. Expression of HPRT remained stable during the investigated period. 
mRNA expression data for APP were confirmed by Western blot analysis using an 
antiserum (anti-APP, see table 2) that detects the APP770 isoform which is 
predominantly expressed in glial cells (Lee and Wurtman, 2000). Anti-Actin 
antibodies were used to visualize actin as loading control (anti-actin, see table 2; 
(data not shown).  
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The applied APP antibody detects the 110 kDa APP holoprotein as well as various 
smaller cleavage products and immature isoforms (information kindly provided by the 
manufacturer). A representative blot is presented in figure 11B. Increased APP 
reactivity could be observed after one week cuprizone treatment. When 
demyelination processes, APP protein levels remained higher compared to controls. 
Thus, the time course of APP protein induction parallels APP and GFAP mRNA 
levels. As shown in figure 11B, predominantly proteins with a molecular weight at 50 
kDa appear to accumulate within the demyelinated CC compared to controls. These 
products most likely represent cleaved APPs. In contrast, accumulation of the APP 
Figure 10 (A) Myelination and inflammatory cell composition in the midline of corpus callosum (CC) 
of control (upper row) and cuprizone-induced demyelinated (cu) brains (lower row). Anti-PLP 
antibodies were used to visualize myelin, anti-GFAP antibodies to visualize astrocytes, and anti-Iba1 
antibodies to visualize microglia/macrophages. Anti-APP immunohistochemistry of control and 
cuprizone brains are presented in (B). Immunofluorescence double-labelling for APP and GFAP of 
cup animals are given in (C). Note that massive myelination (brown staining) is apparent in the CC of 
control animals, whereas after acute demyelination (5 weeks cuprizone treatment) the midline of CC is 
almost completely demyelinated. Further note the robust increase in GFAP and Iba1-positive cells, 
respectively. APP-positive cells are rarely detectable in control animals. In contrast, numerous APP-
positive cells are visible after cuprizone exposure. The insert in (B) shows an APP-positive cell at 
higher magnification.  APP positive cells also express GFAP (arrowhead in C). Scale bars: 25 µm in 
A; 50 µm in B; 20 µm in C. 
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holoprotein with a molecular weight at 110 kDa was not observed in response to 
demyelination. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Astrocytes fulfil many important functions within the CNS ranging from directing 
neuronal differentiation to regeneration, regulating inflammatory processes, and 
protecting nerve cells under pathological conditions. In a previous study, we have 
analyzed growth factor expression of differentially stimulated cultured cortical 
astrocytes. These data show that astroglia selectively respond to pathological 
compounds by the expression of growth factors (Braun et al. 2009). In contrast to the 
cuprizone model where only astrocytes seem to express APP, microglia cells in the 
EAE model are also APP-positive (Banati et al. 1995a). In human MS lesion, both cell 
types are potential sources of APP depending on the stage of the disease (Banati et 
al. 1995a; Gehrmann et al. 1995). It appears that complex cell-cell interactions are 
required to induce APP expression in astrocytes. We therefore reason that the 
induction of APP in astroglia is highly selective and not the result of an unspecific 
activation. This assumption was reassessed in primary astrocyte cultures prepared 
from one to three-day-old Balb/c mice cortices. Cultures were treated with LPS, 
Figure 11 Time-dependent expression of APP mRNA (A) and protein (B) is shown. Induction of APP could 
be observed already after one week of cuprizone exposure. PCR showed an early up-regulation of both APP 
and GFAP mRNA expression, indicating a similar temporal induction pattern. HPRT served as loading 
control in PCR experiments. Note the selective increase in cleavage products (50 kDa) of the APP-
holoprotein (110 kDa) reactivity. 
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TNFα, glutamate or H2O2 for 24 h. Previous studies revealed that the applied 
concentrations are sufficient to activate astrocytes, however, are not toxic in the 
applied concentrations (Braun et al. 2009).  APP mRNA expression was analyzed by 
real-time RT-PCR. As shown in fig. 12A agarose gel analysis of PCR products (30 
cycles) revealed only moderate levels of APP mRNA in untreated cultures. As 
expected, the exposure to the different toxic compounds did not further increase 
endogenous APP levels in astrocytes (fig. 12B) significantly. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12 (A)  Basal expression levels of APP in cortical astrocytes analyzed by semi-quantitative PCR 
(30 cycles) and agarose gel analysis. Results of real-time RT-PCR gene expression analysis are shown 
in (B). Toxin data are given as percentiles with control values set to 100%. All data were normalized 
against HPRT expression as a housekeeping gene. Data represent means ± SEM. APP is already 
expressed in control cultures. None of the stimuli applied induces significantly APP expression.  
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6.3 Discussion 
The amyloid precursor protein (APP) has been under intensive study in recent years 
mainly due to its critical role in the pathogenesis of Alzheimer's disease (Guo et al.). 
APP is a type I trans-membrane glycoprotein that is constitutively expressed in 
different mammalian cell types. It is post-translational processed by protelytic 
secretase cleavage, leading to different APP-fragments (Tanzi and Bertram 2005). 
Despite intensive research and the fact that APP is ubiquitously expressed in many 
mammalian cells,, not much is known about the physiological roles of this protein 
under non-pathological conditions (Clarner et al. 2011a). It has been shown that the 
soluble and secreted form of APP (sAPP) shows similarities with growth factors and 
increases the in vitro proliferation of embryonic neural stem cells. In the 
subventricular zone (SVZ), i.e. the brain region where postnatal neurogenesis takes 
place, sAPP induces proliferation of EGF-positive neuronal progenitors (Caille et al. 
2004). A clear expansion of the SVZ, based on the increase in cell density (2-3 fold) 
and proliferation has been shown in MS patients compared with controls. These 
findings correlated with elevated numbers of PSA-NCAM and GFAP-positive cells 
(Nait-Oumesmar et al. 2007). Our observations and reports from other groups show 
that the SVZ is activated in cuprizone-treated animals as well. However, we did not 
find increased APP immunoreactivity within the SVZ of cuprizone-treated animals. 
Therefore, APP might be exclusively involved in neurogenesis but not gliogenesis 
(Clarner et al. 2011a). 
Beta-amyloid (Aβ), a peptide generated from APP, is widely believed to underlie the 
pathophysiology of Alzheimer’s disease (Minano-Molina et al. 2011). In the so called 
“amyloidogenic pathway”, APP cleavage by β- and γ-secretases generates Aβ-
peptides which are the main constituents of senile plaques in this disease. Familial 
early-onset Alzheimer’s disease can be connected to mutations in the APP gene 
(Tanzi and Bertram 2005). Not only Alzheimer’s disease,but also the pathogenesis of 
other neurodegenerative disorders such as Niemann-Pick type C disease (Jin et al. 
2004) and Down Syndrome can be associated to APP (Isacson et al. 2002). Beyond 
APP involvement in disease pathogenesis, the protein has been shown to be multi-
facetted in function and can be induced as an acute phase protein by several cell 
types in the brain as response to cellular injury (Banati et al. 1993) or ischemia 
(Stephenson et al. 1992). If sufficently stimulated, virtually all brain resident cell types 
seem to be able to express APP (Gehrmann et al. 1995).    
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In demyelinating disorders like MS, not much is known about the role and expression 
of APP. Gehrmann et al. investigated six histopathologically normal control and six 
MS cases for presence of APP-positive cells (Gehrmann et al. 1995). They found low 
APP immunoreactivity in healthy subjects, whereas high levels of APP 
immunoreactivity can be seen in actively demyelinating lesions The amount of 
positively-stained cells depended on the lesion stage and was generally lower in 
more chronic lesions compared to acute forms. While in active lesions astrocytes, 
microglia, foamy macrophages, and T-cells stained positive for APP, the 
immunoreactivity was restricted to reactive astrocytes, their processes, and a few 
macrophages/microglia in more chronic lesions. The results presented by the 
Gehrmann group clearly demonstrate that APP is induced in reactive glial cells but 
equally in T-cells during demyelination (Gehrmann et al. 1995). The same group also 
demonstrated, that APP is expressed by microglia/macrophages in T-cell-mediated 
EAE (Banati et al. 1995a).  
To obtain further information about expression pattern and possible role of APP 
during CNS demyelination, we have extended our study to toxic demyelination 
lesions using the cuprizone model (Clarner et al. 2011a). APP staining can be used 
as a marker for acute neuronal damage in this model (Lindner et al. 2009). However, 
induction of APP immunoreactivity in glia cells as a response to cuprizone 
intoxication has not been reported elsewhere. Three major isoforms of APP, 
consisting of 695 (small amounts), 751 or 770  amino acids (APP 770, APP 751 and 
APP 695) have been shown to be produced by astrocytes in culture (Rohan de Silva 
et al. 1997; Shepherd et al. 2000). The ratios of these isoformes appears to be  
connected to changes in the protein function (Gray and Patel 1993; Shepherd et al. 
2000). The antibody we used in cuprizone-intoxicated mice is thought to react with 
the APP 770 isoform,but is predicted to react with APP 751 and 695 as well (Clarner 
et al. 2011a). We, therefore, cannot state which of the isoforms is present in 
astrocytes of cuprizone-treated animals (Clarner et al. 2011a). Importantly, we did not 
detect APP-positive oligodendrocytes or microglia cells in this animal model. As 
already mentioned and in contrast to the EAE model where APP-positive 
oligodendrocytes and microglia can be found (Banati et al. 1995a), no invasion of 
autoimmune T-cells takes place during cuprizone-induced demyelination (Kipp et al. 
2009; Matsushima and Morell 2001). Our results indicate that different mechanisms 
of demyelination in the mentioned models lead to different responses of astrocytes, 
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microglia, and oligodendrocytes (Clarner et al. 2011a). A possible explanation for 
these differences could be the need of T-cell-derived stimuli to induce APP-
expression in microglia and oligodendrocytes but not astrocytes. However, results of 
our cell culture experiments strongly suggest that, in astrocytes, the simultaneous 
application of different stimulatory factors appears to be critical to induce APP 
expression (Clarner et al. 2011a). We cannot completely exclude the possibility that 
the observed immunoreactivity in our model is due to internalized APP of a non-
astrocytic source, since it is well-known that astrocytes can bind and internalize APP 
products in vitro and in vivo (Alarcon et al. 2005; Nagele et al. 2003). However, if this 
is the case, one would expect that also microglia would stain positive for APP, since it 
has also been shown that microglia are able to internalize APP products (Mandrekar 
et al. 2009). Furthermore, the applied antibody reacts most strongly with the glial 770 
amino acid isoform of APP (Clarner et al. 2011a). 
The precise role of astroglia-derived APP during toxic demyelination and reparative 
processes in the CNS needs to be further investigated. What we have learned from 
our model is that it perfectly mimics several aspects of MS disease progression and 
pathology and, therefore, is a suitable in vivo tool to further follow up the open 
questions. 
  
 
 69
7. General discussion  
 
Research concerning neurodegenerative diseases, such as MS, largely depends on 
valuable animal models. Due to the extreme complexity of MS, various substantially 
distinct mouse models are frequently used to investigate certain aspects of the 
disease. One of these models is the cuprizone mouse model for de- and 
remyelination. In the following part, I will discuss in detail the advantages and 
limitations of cuprizone intoxication as a model for MS in the cerebellum, the basal 
ganglia system, and the hippocampus region. One outstanding hallmark of MS 
pathology which is dissemination in space was addressed in this animal model. 
In all investigated brain areas, regions which are vulnerable to the cuprizone 
challenge have been found (Groebe et al. 2009; Norkute et al. 2009; Pott et al. 
2009). In contrast, some regions seem to be partially protected. The cerebellar white 
matter, the medial basal ganglia compartment, and the hippocampal fimbria are 
almost completely resistant to cuprizone intoxication. In contrast, the CC, the 
cerebellar nuclei located in the cereballar marrow, and the lateral parts of the basal 
ganglia are highly vulnerable. One reason for this “partial protection” might be the 
spatial relation of the affected regions to the liquor system. The brain areas which 
were found to be protected are often located close to the ventricle system and might 
therefore be more effectively supplied with trophic and angiogenic factors via the 
cerebrospinal fluid (CSF). The CSF additionally plays an important role in the 
clearance of toxins and drugs (Redzic et al. 2005) and might therefore reduce the 
accumulation of toxins in the tissue. This might, at least in part, be the reason for the 
observed basal ganglia demyelination pattern. What argues against this hypothesis 
are our observations made in the cerebellum. There, the cerebellar peduncels as well 
as the nuclei located within the deep cerebellar marrow are not resistant to the 
cuprizone-challenge (Groebe et al. 2009). 
A quite obvious reason for the observed region-specific vulnerability could be 
differences in the repair capacity of distinct brain regions. This seems to be especially 
true for the medial basal ganglia, a compartment in very close contact to the sub-
ventricular zone (SVZ) where OPC are believed to originate (Gonzalez-Perez et al. 
2009). Our observations indicate that the SVZ is activated during early cuprizone 
administration. Compared to controls, the SVZ showed a 2-3 fold increase in cell 
density during cuprizone treatment. Concordantly, proliferating cells can be found 
more frequently within the SVZ of the acute demyelinated brain. Further studies have 
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to show whether brain region specific vulnerability to the cuprizone challenge are 
attributable to repair processes.  
Region-specific brain-intrinsic inflammatory processes might be another underlying 
mechanism. Our group was recently able to show that primary astrocyte cultures, 
isolated from two different brain regions (midbrain vs. cortex), differ with respect to 
the expression and release of inflammatory mediators under control conditions and 
after stimulation (Kipp et al. 2008). Thus, astrocytes and microglia likely display 
region specific responses in vivo, as well. We and others were able to show that 
apoptotic cells and loss of oligodendrocytes can be found in both, affected (for 
example within the CC) as well as “protected” areas, i.e. the fimbria region or the 
spinal cord (Herder et al. 2011; Kipp et al. 2011). Furthermore, early microglia 
activation is evident in protected and vulnerable brain regions. One might speculate 
that the progression of those early lesions to demyelinated ones depends on brain 
region-specific astrocyte and microglia function. In this context, findings from Hesse 
and colleagues are noteworthy. Their results suggest that the underlying mechanism 
of oligodendrocytes cell death is not the same during early vs. late cuprizone 
treatment (Hesse et al. 2010). They observed that in early but not in later stages 
dying oligodendrocytes express activated caspase 3. It might be that region specific 
microglia activity modulates lesion progression during caspase 3-independent 
oligodendrocytes death stages.  
A common feature of all affected brain regions is the activation and proliferation of 
astroglia inside or nearby the demyelinated areas. An ambivalent role has been 
discussed for this cell type during acute demyelination, since both, astrocyte-derived 
harmful chemokines and prostaglandins as well as important growth factors are 
synthesized during acute demyelination (Barres 2008; Brambilla et al. 2009). It is 
apparent that astrocytes possess a dual role in disease progression which appears to 
be destructive at the onset and during acute demyelination but might become 
supportive in later stages of disease. As shown in chapter 2, astrogliosis persists 
during effective endogenous remyelination, whereas microglia numbers are 
diminished at both 9 and 21 days of remyelination (Clarner et al. 2011b), arguing for 
a supportive role of astrocytes during ongoing remyelination.  
At a very early time point of cuprizone intoxication (2 days), microglia activation and 
proliferation can be found preceding accumulation and activation of astrocytes and 
demyelination by weeks (unpublished data from our group). Most of the highly 
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affected brain areas showed strong microglia activation/proliferation and higher 
microglia numbers could be related to more severe demyelination (Pott et al. 2009). 
Interestingly, demyelinated grey matter parts of the hippocampus showed no 
increased microglia numbers (Norkute et al. 2009). The role of microglia in the 
progression of an early (microglia activation and oligodendrocyte apoptosis but no 
demyelination or astrogliosis) towards an actively demyelinating lesion, remains 
speculation so far and is currently under investigation by our group.  
In summary, the first part of this thesis clearly shows that certain aspects of MS, such 
as grey matter pathology, dissemination in space and brain intrinsic inflammation are 
closely mirrored in the cuprizone model. Therefore, this model can be used to 
elucidate the principle mechanisms of both acute demyelination and reparative 
processes, i.e. remyelination. One should notice that the importance of lymphocyte-
driven inflammation declines with disease duration. While widespread lymphocyte 
infiltration is characteristic for the relapsing-remitting disease course (Lucchinetti et 
al. 2000), microglia/macrophages become more dominant during the progressive 
disease stages (van der Valk and De Groot 2000). Hence, the cuprizone model can 
be used to study progressive MS pathology but is certainly less valuable for studying 
early MS disease course. 
Preventing the onset of demyelination would be the most effective treatment for MS 
patients. However, understanding the cause of the disease is a prerequisite to 
achieve this goal. So far, high doses of CS are the standard treatment during acute 
inflammatory relapses. Undoubtedly, CS are beneficial during acute inflammatory MS 
exacerbations. They effectively manage autoimmune relapses by dampening the 
deleterious inflammatory events in the brain. Besides relapse management, 
facilitating remyelination became a important research goal, since remyelination can 
protect axons from degeneration (Irvine and Blakemore 2008) and thereby prevents 
the progression of irreversible functional deficits. 
Substances that are known to promote the differentiation of OPC in vitro are retinoic 
acid, thyroid hormone T3, and CS (Barres et al. 1994; Clarner et al. 2011b). These 
substances are thought to act via a quite similar mechanism, timing oligodendrocyte 
development (Barres et al. 1994). Both, retinoic acid and T3 hormones have been 
investigated for their potential to facilitate remyelination in vivo. A recent study 
utilizing a toxic demyelination/remyelination model convincingly showed that retinoid 
receptor signalling accelerates CNS remyelination (Huang et al. 2011). Furthermore 
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T3 hormone injections led to differentiation of cells originating in the SVZ towards 
progenitors with migrating properties. These OPC can actively invade demyelinated 
tissue and facilitate remyelination (Franco et al. 2008; Harsan et al. 2008). In 
contrast, and despite the already mentioned effects on OPC in vitro, our own study 
clearly shows that CS are not promoting remyelination, but impair myelin restoration 
in the CC. The underlying mechanisms of these effects seem to be independent from 
thyroid hormone signalling (Clarner et al. 2011b). We hypothesize that the negative 
net effect on remyelination is mediated by indirect effects on OPC. Most likely, CS-
induced changes in the growth factor release of astrocytes are involved in influencing 
OPC myelination capacity. We could show that not only OPC but also astrocytes 
respond to CS treatment. We observed changes in the growth factor expression 
levels, e.g. FGF2 and PDGF-αα in relation to IGF-1. The role of these growth factors 
has been investigated with respect to remyelination in the cuprizone animal model. 
On one hand, the combination of FGF-2, PDGF-αα, IGF-1 and Neurotropin 3 (NT3) 
has been shown to activate proliferation of neural cells and drive their differentiation 
into mature oligodendrocytes that can remyelinate axons in demyelinating lesions 
(Kumar et al. 2007). On the other hand, studies on cuprizone-treated FGF2-null mice 
showed that FGF2 signalling is an effective component limiting remyelination of 
chronically demyelinated lesions (Tobin et al. 2011). For PDGF-αα, it has also been 
reported that elevated expression of human (h)PDGF by astrocytes prevented 
oligodendrocyte apoptosis following cuprizone treatment (Vana et al. 2007). In 
addition, a single intracerebral injection of PDGF in a chemically induced 
demyelination rodent model (lysolecithin) increased numbers of mature 
oligodendrocytes and enhanced remyelination (Allamargot et al. 2001; Moore et al. 
2011). In this context, the results of chapter II highlight the need of appropriate 
animal models to validate in vitro data dealing with OPC differentiation and the 
importance to further understand the complex interplay of different brain cell types.  
Recently, Wang and colleagues showed that GC treatment leads to increased 
deposition of astrocyte derived amyloid-β protein (APP-β) and decreased APP 
clearance in both, cultured astrocytes and in vivo (Wang et al. 2011). APP is a 
protein that has been found to have neurotrophic or neuroprotective properties in its 
secreted form (Lee and Wurtman 2000; Thinakaran and Koo 2008). Beyond that, it 
also is involved in the pathogenesis of Alzheimer’s disease when spliced in the so 
called amyloidogenic pathway that generates APP-β. Astrocytes are thought to be an 
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important source of APP-β (Blasko et al. 2000; Wang et al. 2011) and APP might 
therefore play a role in both the neuroprotective as well as the deleterious properties 
of astrocytes. Since ongoing research of our group focuses on astrocyte function 
during acute demyelinating CNS damage and since astrocytes were found to express 
high levels of APP in MS lesions (Gehrmann et al. 1995), we aimed to investigate, 
whether the cuprizone model might be a suitable tool to study glia derived APP 
functions. We found activation of APP expression exclusively in astrocytes as a 
response to cuprizone challenge. Our results (Chapter III) indicate that APP 
expression by astrocytes depends on the simultaneous stimulation of different factors 
and is not a general reaction to activation. Interestingly, microglia does not express 
APP in the cuprizone model. Therefore, cuprizone intoxication might be a unique tool 
to study astrocyte-derived APP functions without interference of other glia cells. 
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8. Summary 
(English) 
Multiple sclerosis is a widespread demyelinating disease where primary 
oligodendrocyte dysfunction represents a possible underlying mechanism of myelin 
loss. Cuprizone intoxication which causes primary oligodendrocyte apoptosis, mimics 
some aspects of this disease. In the first part of my thesis, the extent and pattern of 
demyelination in this MS animal model was analyzed. Additionally, the innate 
immune responses to the cuprizone challenge were investigated. Our results 
regarding the  cerebellum were included in this thesis, and the different pattern of 
demyelination in the basal ganglia, hippocampus, and cerebellum was highlighted. 
Striking differences were found in the magnitude of demyelination between different 
white and grey matter areas. Distinct cerebellar white matter regions, the cerebellar 
cortical grey matter, the medial basal ganglia, and the hippocampal fimbria were 
resistant to the cuprizone challenge. In contrast, other regions displayed severe 
myelin loss and activation of microglia and astroglia. We discuss the advantages and 
limitations of this model with regard to regional differences and “protection”.  
In the second part of this work, we used the cuprizone model to investigate the 
impact of corticosteroid (CS) treatment on spontaneously remyelinating lesions and 
addressed the underlying mechanisms by several in vitro and in vivo approaches. We 
are able to demonstrate that while CS-treatment accelerates the differentiation of 
oligodendrocyte progenitors in vitro, it impairs endogenous remyelination in vivo. We 
additionally identified CS-induced changes in the growth factor expression profile of 
cultured astrocytes that might explain the impairment of repair processes in the brain. 
The importance of astrocytes for early and late repair processes was further 
highlighted by our finding that astrocytosis but not microgliosis persists after an acute 
demyelinating event. Our data clearly show that promotion of the intrinsic 
oligodendroyte differentiation program might negatively affect myelin repair in vivo. 
We speculate that CS treatment induces a preterm oligodendrocytes differentiation 
and, thus, might impair endogenous remyelination cascades. Furthermore, beneficial 
steroidal effects during inflammation have to be balaced against possible 
remyelination-inhibiting effects.  
In the third part of the presented thesis, we focused on astrocyte’s response during 
an acute demyelinating event. The amyloid precursor protein (APP) which is well 
known to be expressed in activated astroglia, microglia and stressed neurons in 
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several disease models, was in the focus of the study. We found that the expression 
of APP is strongly induced during acute cuprizone-induced demyelination. 
Exclusively astrocytes express APP during cuprizone-induced demyelination. Our in 
vitro experiments using primary astrocyte cultures indicate that this is a highly 
specific response to toxic demyelination. The cuprizone model, therefore, is a 
suitable tool to study the role of astrocyte derived APP in a MS animal model.  
The results of my thesis significantly broaden the knowledge regarding the potential 
of the cuprizone model as a tool for studying underlying mechanisms of de- and 
remyelination.  
 
(German) 
Die Multiple Sklerose ist eine weitverbreitete Entmarkungserkrankung, bei der die  
primäre Apoptose von Oligodendrozyten einen grundelegenden Mechanismus des 
Myelinverlustes darstellt. Das Cuprizone Tiermodell verursacht primäre 
Oligodendrozytenapoptose und spiegelt daher einige Aspekte der Erkrankung wider.  
Im ersten Teil meiner Dissertation wurden das Ausmaß der Demyelinisierung und ihr 
Verbreitungsmuster in diesem Modell analysiert. Zusätzlich wurden die Reaktionen 
des angeborenen Immunsystems untersucht. Unsere das Cerebellum betreffenden 
Befunde wurden in diese Arbeit mit aufgenommen und ein Vergleich der 
Demyelinisierungsmuster zwischen den Basalganglien, dem Hippocampus und dem 
Cerebellum gezogen. 
Wir konnten auffällige Unterschiede in der Ausprägung der Demyelinisierung 
zwischen den untersuchten Bereichen der grauen und weißen Substanz feststellen. 
Bestimmte Bereiche der cerebellaren weißen Substanz und der grauen Substanz des 
cerebellaren Cortex, die medialen Basalganglien und die Fimbrienregion des 
Hippocampus waren resistent gegen Cuprizone induzierte Demyelinisierung. 
Im Gegensatz hierzu zeigten andere Bereiche ausgeprägten Myelinverlust und 
Aktivierung von Mikro- und Astroglia. Wir diskutieren die Vorteile und Limitationen 
des Cuprizone Modells mit Bezug auf regionale Unterschiede und „Protektion.“ 
Im zweiten Teil dieser Arbeit verwendeten wir das Cuprizone Modell um den Einfluss 
von Korticosteroiden (KS) auf spontan remyelinisierende Läsionen zu untersuchen. 
Sowohl in vitro als auch in vivo Versuchsansätze wurden verwendet um die 
zugrundeliegenden Mechanismen dieses Einflusses zu untersuchen. Wir konnten 
zeigen, dass KS zwar die Ausreifung von Oligodendrozyten Progenitorzellen in vitro 
beschleunigen, die endogene Remyelinisierung in vivo jedoch verschlechtern. 
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Zudem fanden wir Änderungen im Expressionsprofil astrozytengenerierter 
Wachstumsfaktoren in Zellkultur. Diese Änderungen könnten die Verschlechterung 
der Reparaturprozesse im Gehirn erklären. Unsere Ergebnisse zeigen das die 
Astrogliose, im Gegensatz zur Mikrogliose, in der Phase nach einem akuten 
demyelinisierenden Ereignis persistiert. Diese Beobachtungen untermauern die 
Bedeutung von Astrozyten für frühe und späte Reparaturvorgänge. Unsere 
Ergebnisse zeigen zudem, dass das Vorantreiben des intrinsischen 
Differenzierungsprogramms von Oligodendrozyten die Myelinreparatur in vivo negativ 
beeinflussen kann. Wir spekulieren, dass die Behandlung mit KS ein verfrühtes 
Ausreifen von Oligodendrozyten verursacht und dadurch die 
Remyelinisierungsvorgänge negativ beeinflusst. Daher sollten die vorteilhaften 
Steroideffekte während akuter Entzündungsreaktionen gegen mögliche 
remyelinisierungshemmende Effekte abgewogen werden. 
Im dritten Teil dieser Dissertation fokussierten wir uns auf die Astrozytenantwort 
während akuter Demyelinisierung. Das Amyloid Vorläuferprotein (APP), von dem 
man weiß das es sowohl von aktivierten Astro- und Mikroglia, als auch von 
gestressten Neuronen exprimiert wird, stand dabei im Mittelpunkt. Wir fanden heraus, 
dass die APP-Expression nach Cuprizone induzierter Demyelinisierung verstärkt 
wird. Die APP Expression ist dabei auf Astroyzten beschränkt. Unsere in vitro 
Experimente weisen darauf hin das dies eine hochspezifische Reaktion auf toxische 
Demyelinisierung ist. Daher stellt das Cuprizone Modell ein geeignetes Werkzeug zur 
Untersuchung der Rolle von astrozytärem APP dar. 
Die Ergebnisse meiner Dissertation erweitern das Wissen darüber, inwiefern das 
Cuprizone Modell als Instrument für das Studium der zugrundeliegenden 
Mechanismen von De- und Remyelinisierung dienen kann. 
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13. Appendix 
 
13.1 Appendix 1: Transcardial perfusion of mice 
 
Perfusion Solution 
 
- Heat 800ml of distilled water to app. 60°C 
- Dissolve 3.3g NaH2PO4xH2O (Natriumdihydrogenphosphat-Monohydrat, Carl-
Roth, Germany) and 45g Na2HPO4x12H2O (di-Natriumhydrogenphosphat-
Dodecahydrat, Carl-Roth, Germany) 
- Dissolve 20g paraformaldehyde (Sigma-Aldrich; Germany) 
- Add 100ml saturated picric acid (Sigma-Aldrich; Germany) 
- Let cool down to room temperature, set the pH to 7.4 and add bi-distilled water 
to 1000ml 
- Filter, and cool down to 4°C.  
 
Procedure 
 
- 30min prior to start, apply 10µl Clexane-40mg (Sanofi-aventis, Germany) by 
intraperitoneal injection.  
- Deeply anaesthetise animals with Isolfuran (5%) 
- Fix the animal, open the thorax by using forceps and scissors and cut a small 
opening into the right heart atrium.  
- Insert a small needle into the left heart ventricle and perfuse 50ml of ice-cold 
perfusion solution.  
- Cut the head and/or the trunk 
- Incubate the tissue samples overnight at 4°C in the same fixative. 
- Dissect the brain/spinal cord and store in 1:5 diluted (in PBS) perfusion 
solution at  
4°C until used. 
 
 
13.2 Appendix 2: Paraffin-embedding of mice tissue samples 
 
Since paraffin is immiscible with water, tissue needs to be dehydrated by 
progressively more concentrated ethanol baths. This is followed by a clearing agent, 
usually xylene or Histo-clear, to get rid of the ethanol. Finally, tissue is put into molten 
paraffin wax (60°C). The wax is changed 3 times to get red of xylene residues. 
 
 
Tissue samples were embedded in paraffin by immersing them under gentle agitation 
for the desired time in 
 
- 70% Ethanol:   3 x 30min 
- 96% Ethanol    3 x 30min 
- 100% Ethanol   3 x 30min 
- Histo-Clear (Biozym, Germany) 3 x 60min 
- Paraffin (xx, Germany)  3 x 120min and then overnight at 60°C 
 
Thereafter, tissue samples were embedded in paraffin. 
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13.3 Appendix 3: Immunohistochemistry 
 
Reagents: 
 
Tris/EDTA buffer: 
 
- Dissolve 1.21 g Tris-(hydroxymethyl)-aminomethan (Carl-Roth, Germany) and 
0.37 g ethylenediaminetetraacetic acid (Carl-Roth, Germany) in 900 ml bi-
distilled water. 
- Set pH to 9.0 and add bi-distilled water to 1000ml 
- Add 0.5ml Tween® 20 (Sigma-Aldrich, Germany) 
 
 
Sodium citrate buffer: 
 
- Dissolve 2.94 g Sodium citrate dehydrate (Sigma-Aldrich Germany) in 900 ml 
bi-distilled water 
- Set pH to 6.0 and add bi-distilled water to 1000ml 
- Add 0.5ml Tween® 20 (Sigma-Aldrich, Germany) 
 
 
Procedure: 
 
- Deparaffinise and rehydrate cutted sections in xylol (4 x 5min), 100% Ethanol 
(3 x 2min), 96% Ethanol (2 x 2min), 70% Ethanol (2 x 2min) and PBS (1 x 
5min).  
- Perform heat-mediated antigen retrieval where necessary (compare to table 2) 
by boiling slides in the desired buffer. Either use Tris/EDTA (10 mM Tris Base, 
1 mM EDTA Solution, 0.05% Tween 20, pH 9.0) or Sodium citrate buffer (10 
mM Sodium citrate, 0.05% Tween 20, pH 6.0). Set a microwave to full power 
and wait until the solution comes to the boil. Heat for 20 minutes from this 
point without boiling. Let slides cool down to room temperature 
- Wash in PBS (3 x 5min) 
- Block endogenous peroxidase activity by incubating slides for 30 min in 0.3% 
hydrogen peroxide (Carl-Roth, Germany) diluted in PBS.   
- Wash in PBS (3 x 5min) 
- Block unspecific bindings of secondary anti-mouse antibodies by incubating 
the slides in blocking solution for 1 h at room temperature.  
- Decant the blocking solution and apply the primary antibody over night at 4 °C 
diluted in blocking solution. Use a wet chamber to avoid drying-out of the 
slides.  
- The next day, decant the primary antibody and wash in PBS (3 x 5min) 
- VECTASTAIN® ABC (peroxidase) system (vectorlabs, USA) are used to label 
primary antibody-antigen conjugates following the manufacturer`s 
recommendation.  
- Wash in PBS (3 x 5min) 
- Incubate the slides in aminoethyl carbazole (Invitrogen, Germany) for up to 30 
min in room temperature to visualize antibody-antigen conjugates.  
- Counterstain with haematoxylin to visualize cell nuclei if desired  
- Mount slides in Kaiser’s glycerine gelatine. 
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12.4 Appendix 4: SDS Polyacrylamid gel electrophoresis 
 
Protein expression can be semi-quantitatively determined by separating denaturated 
proteins by SDS gel electrophoresis on polyacryamid gels followed by western blot 
analysis. Proteins with a high molecular mass cross the gel more slowly compared to 
smaller proteins. Separated proteins are then blotted on nitrocellulose membranes 
and can be labeled by appropriate primary antibodies. Visualization is performed on 
x-ray films utilizing horse radish peroxidase coupled secondary antibodies and a 
chemoluminescence reagent. 
 
Reagents: 
4x Resolving buffer  
Tris-OH (1,5M = 36,94g) 
SDS (0,4% = 0,8g) 
pH 8,8 
fill up to 200ml with H2O
 
4x Stacker buffer  
Tris-Cl (0,6 M = 18,91g) 
SDS (0.4% = 0.8g) 
pH 6,8 
fill up to 200ml with H2O
 
Preparation of gels 
Polyacrylamid gels consist of two phases, a high concentrated resolving gel and a 
lower concentrated stacker gel. 
 
For 1 resolving gel (8%) mix: 
 
 
Water                                                                                            2.2ml
40% Acrylamide (Rotiphorese gel 40, Roth, Germany)           0.8ml
Resolving buffer                                                                          1.0ml
10% APS (Sigma, Germany)                                                       40µl 
Temed (Roth, Germany)                                                               4µl 
 
 
Let the resolving gel polymerize (app. 30min at room temperature), then a lower 
concentrated stacker gel is made consisting of: 
 
Water                                                                                       0.781ml
40% Acrylamide (Rotiphorese gel 40, Roth, Germany)      0.162ml
Stacker buffer                                                                         0.312ml
10% APS (Sigma, Germany)                                                  12.5µl 
Temed (Roth, Germany)                                                           1.2µl 
 
 
After complete polymerization (additional 30min), the gel is ready for use in SDS-
PAGE. Proteins are separated by 120V for 10min followed by 140V for 1h. 
 
